UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 10-Q
(Mark One)
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended June 30, 2023March 31, 2024
OR
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from                     to                     

Commission File Number: 001-39390
GOCO_Logo1.jpg
GoHealth, Inc.
(Exact name of registrant as specified in its charter)
_________________________
Delaware85-0563805
(State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification No.)
214 West Huron St.222 W Merchandise Mart Plaza, Suite 175060654
Chicago,Illinois
(Address of principal executive offices)(Zip Code)
(312) 386-8200
(Registrant’s telephone number, including area code)

N/A
(Former name, former address and former fiscal year, if changed since last report)
_________________________



Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange
on which registered
Class A Common Stock,
$0.0001 par value per share
GOCOThe Nasdaq Global Market
Indicate by check mark whether the registrant:registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes      No  
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes      No  
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filerAccelerated filer
Non-accelerated filer Smaller reporting company
Non-accelerated filerEmerging growth company
Accelerated filer
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes      No  
As of August 2, 2023,May 1, 2024, the registrant had 9,511,8609,946,669 shares of Class A common stock, $0.0001 par value per share, outstanding and 12,817,92212,781,528 shares of Class B common stock, $0.0001 par value per share, outstanding.


TABLE OF CONTENTS
PAGE
PART I - FINANCIAL INFORMATION
ITEM 1.
ITEM 2.
ITEM 3.
ITEM 4.
PART II - OTHER INFORMATION
ITEM 1.
ITEM 1A.
ITEM 2.
ITEM 3.
ITEM 4.
ITEM 5.
ITEM 6.



CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This Quarterly Report on Form 10-Q contains forward-looking statements. We intend such forward-looking statements to be covered bywithin the safe harbor provisions for forward-looking statements contained inmeaning of Section 27A of the Securities Act of 1933, as amended, (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These forward-looking statements are made in reliance upon the safe harbor provision of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q may be forward-looking statements. Statements regarding our future results of operations and financial position, business strategy and plans and objectives of management for future operations, including, among others, statements regarding our expected growth, future capital expenditures and debt service obligations, are forward-looking statements.

In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “aims,” “expects,” “plans,” “anticipates,” “could,” “intends,” “targets,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential,” “likely,” “future” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this Quarterly Report on Form 10-Q are only predictions.predictions, projections and other statements about future events that are based on current expectations and assumptions. Accordingly, we caution you that any such forward-looking statements are not guarantees of future performance and are subject to risks, assumptions and uncertainties that are difficult to predict. Although we believe that the expectations reflected in these forward-looking statements are reasonable as of the date made, actual results may prove to be materially different from the results expressed or implied by the forward-looking statements.
These forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q and are subject to a number of important factors that could cause actual results to differ materially from those in the forward-looking statements, including the factors described in the sections titled “Summary Risk Factors,” “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022 (the “2022 Form 10-K”), the section titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in this Quarterly2023 (“2023 Annual Report on Form 10-Q10-K”) and in our other filings with the Securities and Exchange Commission.
You should read this Quarterly Report on Form 10-Q and the documents that we reference in this Quarterly Report on Form 10-Q completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
CERTAIN DEFINITIONS
As used in this Quarterly Report on Form 10-Q, unless the context otherwise requires:
we,We,us,“us,our,“our,” the “Company,” “GoHealth”Company,” “GoHealth and similar references refer to GoHealth, Inc., and unless otherwise stated, all of its direct and indirect subsidiaries, including GoHealth Holdings, LLC.LLC (“GHH, LLC”).
Blocker Company”Blocker Company refers to an entity affiliated with Centerbridge that was an indirect owner of LLC Interests in GoHealth Holdings,GHH, LLC prior to the Transactions and is taxable as a corporation for U.S. federal income tax purposes.
Blocker Shareholders” refer to entities affiliated with Centerbridge, the owners of the Blocker Company prior to the Transactions, who exchanged their interests in the Blocker Company for shares of our Class A common stock and cash in connection with the consummation of the Transactions.
Centerbridge” refers to certain investment funds and other entities affiliated with CCP III Cayman GP Ltd., a Cayman Islands exempted company over which CCP III Cayman GP Ltd. has voting control (including any such fund or entity formed to hold shares of Class A common stock for the Blocker Shareholders).
Continuing Equity Owners” refer collectively to direct or indirect holders of LLC Interests and our Class B common stock immediately following consummation of the Transactions, including Centerbridge, NVX Holdings, our Founders, the Former Profits Unit Holders and certain executive officers, employees and other minority investors and their respective permitted transferees who may, following the consummation of our IPO, exchange at each of their respective options (subject in certain circumstances to time-based vesting requirements and certain other restrictions), in whole or in part from time to time, their LLC Interests (along with an equal number of shares of Class B common stock (and such shares shall be immediately cancelled)) for, at our election (determined solely by our independent directors (within the meaning of the listing rules of The Nasdaq Global Market (the “Nasdaq Rules”) who are disinterested)), cash or newly-issued shares of our Class A common stock.
Founders” refer to Brandon M. Cruz, our Co-Founder and Co-Chairman of the Board of Directors and Clinton P. Jones, our Co-Founder and Co-Chairman of the Board.Board of Directors.
Former Profits Unit Holders” refers collectively to certain of our directors and certain current and former officers and employees, in each case, who directly or indirectly held existing vested and unvested profits units, which were
GoHealth, Inc.20232024 Form 10-Q  1


comprised of profits units that have time-based vesting conditions and profits units that have performance-based vesting conditions, of GoHealth Holdings,GHH, LLC pursuant to GoHealth Holdings,GHH, LLC’s existing profits unit plan and who received LLC Interests in exchange for their profits units in connection with the Transactions. LLC Interests received in exchange for unvested profits units remain subject to their existing time-based vesting requirements. ProfitProfits units with performance-based vesting conditions fully vested as such conditions were met in connection with our IPO.
GHH, LLC Agreement”GoHealth Holdings, LLC Agreement refers to GoHealth Holdings,GHH, LLC’s amended and restated limited liability company agreement, as further amended, which became effective substantially concurrently with or prior to the consummation of our IPO.
LLC Interests” refer to the common units of GoHealth Holdings,GHH, LLC, including those that we purchased with a portion of the net proceeds from our IPO.
Norvax” refers to Norvax, LLC, a Delaware limited liability company and a subsidiary of GoHealth Holdings,GHH, LLC.
NVX Holdings” refers to NVX Holdings, Inc., a Delaware corporation that is controlled by the Founders.
Transactions” refer to our IPO and certain organizational transactions that were effected in connection with our IPO, and the application of the net proceeds therefrom.
GoHealth, Inc. is a holding company and the sole managing member of GoHealth Holdings,GHH, LLC, and its principal asset consists of LLC Interests.
KEY TERMS AND PERFORMANCE INDICATORS; NON-GAAP FINANCIAL MEASURES
Throughout this Quarterly Report on Form 10-Q, we use a number of key terms and provide a number of key performance indicators used by management. We define these terms and key performance indicators as follows:
Adjusted EBITDA”Adjusted EBITDA represents, as applicable for the period, EBITDA as further adjusted for certain items discussed in Item 2. “Management’s Discussion and Analysis of Financial Condition and Results of Operations.”
Adjusted EBITDA MarginMargin” refers to Adjusted EBITDA divided by net revenues.
Adjusted Gross Margin per SubmissionSubmission” refers to Sales per Submission less Cost per Submission.
Cash Adjusted EBITDA”Conversion Rate refers to commissionable SubmissionsAdjusted EBITDA plus a decrease or less an increase in the period over qualified prospects.period change in net contract assets.
Cost of SubmissionSubmission” refers to the aggregate cost to convert prospects into Submissions during a particular period. Cost of Submission is comprised of revenue share, marketing and advertising expenses and customerconsumer care and enrollment expenses, excluding associated share-based compensation expense, the impact of revenue adjustments recorded in the period, but relating to performance obligations satisfied in prior periods and such expenses related to our non-EncompassNon-Encompass BPO Services.
Cost per SubmissionSubmission” refers to (x) the aggregate cost to convert prospects into Submissions duringfor a particular period (comprised of revenue share, marketing and advertising expenses and customerconsumer care and enrollment expenses, excluding share-based compensation expense)expense and such expenses related to Non-Encompass BPO Services) divided by (y) either (i) a completed application with our licensed agent that is submitted to the insurance health plan partner and subsequently approved by the health plan partner during the indicated period, excluding applications through our non-Encompass BPO Services or (ii) a transfer by our agent to the health plan partner through the Encompass marketplace during the indicatednumber of Submissions for such period.
EBITDA”EBITDA represents net income (loss) before interest expense, income tax expense (benefit) and depreciation and amortization expense.

“LTV” refers to the Lifetime Value of Commissions, which we define as aggregate commissions estimated to be collected over the estimated life of all commissionable Submissions for the relevant period based on multiple factors, including but not limited to, contracted commission rates, health plan partner mix and expected policy persistency with applied constraints.
Non-Encompass BPO Services” refer to programs in which GoHealth-employed agents are dedicated to certain health plans and agencies we partner with outside of the Encompass operating model.
Sales per SubmissionSubmission” refers to (x) the sum of (i) aggregate commissions estimated to be collected over the estimated life of all commissionable Submissions for the relevant period based on multiple factors, including but not limited to, contracted commission rates, health plan partner mix and expected policy persistency with applied constraints, excluding revenue adjustments recorded in the period, but relating to performance obligations satisfied in prior periods,
GoHealth, Inc.2024 Form 10-Q  2


(ii) non-agency revenue, and (iii) partner marketing and other revenue, divided by (y) the number of Submissions for such period.
“Sales/Cost of Submission” refers to (x) the sum of (i) aggregate commissions estimated to be collected over the estimated life of all commissionable Submissions for the relevant period based on multiple factors, including but not limited to, contracted commission rates, health plan partner mix and expected policy persistency with applied constraints, excluding revenue adjustments recorded in the period, but relating to performance obligations satisfied in prior periods, (ii) Encompassnon-agency revenue and (iii) partner marketing and enrollment services, divided by (y) the number of Submissions for such period.
GoHealth, Inc.2023 Form 10-Q  2


Sales/Cost of Submission” refers to (x) the sum of (i) aggregate commissions estimated to be collected over the estimated life of all commissionable Submissions for the relevant period based on multiple factors, including but not limited to, contracted commission rates, health plan partner mix and expected policy persistency with applied constraints, excludingother revenue, adjustments recorded in the period, but relating to performance obligations satisfied in prior periods, (ii) Encompass revenue, and (iii) partner marketing and enrollment services, divided by (y) the aggregate cost to convert prospects into Submissions (comprised of revenue share, marketing and advertising expenses and customerconsumer care and enrollment expenses, excluding share-based compensation expense) for such period. Sales and Cost of Submission exclude amounts related to non-EncompassNon-Encompass BPO Services.
Submission”Submission refers to either (i) a completed application with our licensed agent that is submitted to the health plan partner and subsequently approved by the health plan partner during the indicated period, excluding applications through our non-EncompassNon-Encompass BPO Services or (ii) a transfer by our agent to the health plan partner through the Encompass marketplaceoperating model during the indicated period.
LTV” refers to the Lifetime Value of Commissions, which we define as aggregate commissions estimated to be collected over the estimated life of all commissionable Submissions for the relevant period based on multiple factors, including but not limited to, contracted commission rates, health plan partner mix and expected policy persistency with applied constraints.
We use supplemental measures of our performance that are derived from our consolidated financial information, but which are not presented in our Condensed Consolidated Financial Statements prepared in accordance with U.S. generally accepted accounting principles (“GAAP”). These non-GAAP financial measures include EBITDA;EBITDA, Adjusted EBITDA and Adjusted EBITDA Margin. Adjusted EBITDA is the primary financial performance measure used by management to evaluate itsthe business and monitor itsthe results of operations. Sales per Submission, Cost per Submission and Adjusted Gross Margin per Submission are also presented on a non-GAAP basis and are key operating metrics used by management to understand the Company’s underlying financial performance and trends.
We use non-GAAP financial measures to supplement financial information presented on a GAAP basis. We believe that excluding certain items from our GAAP results allows management to better understand our consolidated financial performance from period to period and better project our future consolidated financial performance as forecasts are developed at a level of detail different from that used to prepare GAAP-based financial measures. Moreover, we believe these non-GAAP financial measures provide our stakeholders with useful information to help them evaluate our operating results by facilitating an enhanced understanding of our operating performance and enabling them to make more meaningful period to period comparisons. Adjusted EBITDA is used as a basis for certain compensation programs sponsored by the Company. There are limitations to the use of the non-GAAP financial measures presented in this Quarterly Report on Form 10-Q. For example, our non-GAAP financial measures may not be comparable to similarly titled measures of other companies. Other companies, including companies in our industry, may calculate non-GAAP financial measures differently than we do, limiting the usefulness of those measures for comparative purposes.
The non-GAAP financial measures are not meant to be considered as indicators of performance in isolation from or as a substitute for net income (loss)the most directly comparable financial measures prepared in accordance with GAAP and should be read only in conjunction with financial information presented on a GAAP basis. Reconciliations of each of EBITDA, Adjusted EBITDA, Sales per Submission, Cost per Submission and Adjusted EBITDAGross Margin per Submission to its most directly comparable GAAP financial measure net income (loss), are presented in the tables below inwithin Item 2. “Management’s Discussion and Analysis of Financial Condition and Results of Operations” of this Quarterly Report on Form 10-Q. We encourage you to review the reconciliations in conjunction with the presentation of the non-GAAP financial measures for each of the periods presented. In future periods, we may exclude similar items, may incur income and expenses similar to these excluded items and may include other expenses, costs and non-recurringnon-routine items.
GoHealth, Inc.20232024 Form 10-Q  3


PART I - Financial Information
ITEM 1. FINANCIAL STATEMENTS.
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
GOHEALTH, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share amounts, unaudited)
Three months ended Jun. 30,Six months ended Jun. 30,
2023202220232022
Three months ended Mar. 31,
Three months ended Mar. 31,
Three months ended Mar. 31,
2024
2024
2024
Net revenues
Net revenues
Net revenuesNet revenues142,779 158,654 325,937 429,247 
Operating expenses:Operating expenses:
Operating expenses:
Operating expenses:
Revenue share
Revenue share
Revenue shareRevenue share36,422 51,074 81,884 118,997 
Marketing and advertisingMarketing and advertising39,269 44,714 85,012 128,747 
Customer care and enrollment45,536 66,542 87,563 144,997 
Marketing and advertising
Marketing and advertising
Consumer care and enrollment
Consumer care and enrollment
Consumer care and enrollment
Technology
Technology
TechnologyTechnology10,511 10,749 20,054 23,508 
General and administrativeGeneral and administrative37,855 38,106 60,473 67,323 
General and administrative
General and administrative
Amortization of intangible assetsAmortization of intangible assets23,515 23,515 47,029 47,029 
Operating lease impairment charges2,687 24,995 2,687 24,995 
Amortization of intangible assets
Amortization of intangible assets
Total operating expenses
Total operating expenses
Total operating expensesTotal operating expenses195,795 259,695 384,702 555,596 
Income (loss) from operationsIncome (loss) from operations(53,016)(101,041)(58,765)(126,349)
Income (loss) from operations
Income (loss) from operations
Interest expenseInterest expense17,265 12,724 34,156 24,122 
Interest expense
Interest expense
Other (income) expense, net
Other (income) expense, net
Other (income) expense, netOther (income) expense, net21 (13)(32)50 
Income (loss) before income taxesIncome (loss) before income taxes(70,302)(113,752)(92,889)(150,521)
Income (loss) before income taxes
Income (loss) before income taxes
Income tax (benefit) expenseIncome tax (benefit) expense(73)— (117)472 
Income tax (benefit) expense
Income tax (benefit) expense
Net income (loss)
Net income (loss)
Net income (loss)Net income (loss)(70,229)(113,752)(92,772)(150,993)
Net income (loss) attributable to non-controlling interestsNet income (loss) attributable to non-controlling interests(41,287)(69,933)(54,651)(93,691)
Net income (loss) attributable to non-controlling interests
Net income (loss) attributable to non-controlling interests
Net income (loss) attributable to GoHealth, Inc.
Net income (loss) attributable to GoHealth, Inc.
Net income (loss) attributable to GoHealth, Inc.Net income (loss) attributable to GoHealth, Inc.$(28,942)$(43,819)$(38,121)$(57,302)
Net loss per share (Note 7):Net loss per share (Note 7):
Net loss per share of Class A common stock — basic and diluted$(3.27)$(5.28)$(4.41)$(7.14)
Net loss per share (Note 7):
Net loss per share (Note 7):
Net income (loss) per share of Class A common stock — basic and diluted
Net income (loss) per share of Class A common stock — basic and diluted
Net income (loss) per share of Class A common stock — basic and diluted
Weighted-average shares of Class A common stock outstanding — basic and dilutedWeighted-average shares of Class A common stock outstanding — basic and diluted9,122 8,296 9,044 8,023 
Weighted-average shares of Class A common stock outstanding — basic and diluted
Weighted-average shares of Class A common stock outstanding — basic and diluted
The accompanying Notes are an integral part of these Condensed Consolidated Financial StatementsStatements.
GoHealth, Inc.20232024 Form 10-Q  4


GOHEALTH, INC.
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
(in thousands, unaudited)
Three months ended Jun. 30,Six months ended Jun. 30,
2023202220232022
Three months ended Mar. 31,
Three months ended Mar. 31,
Three months ended Mar. 31,
2024
2024
2024
Net income (loss)
Net income (loss)
Net income (loss)Net income (loss)$(70,229)$(113,752)$(92,772)$(150,993)
Other comprehensive income (loss):Other comprehensive income (loss):
Other comprehensive income (loss):
Other comprehensive income (loss):
Foreign currency translation adjustments
Foreign currency translation adjustments
Foreign currency translation adjustmentsForeign currency translation adjustments41 (345)46 (462)
Comprehensive income (loss)Comprehensive income (loss)(70,188)(114,097)(92,726)(151,455)
Comprehensive income (loss)
Comprehensive income (loss)
Comprehensive income (loss) attributable to non-controlling interests
Comprehensive income (loss) attributable to non-controlling interests
Comprehensive income (loss) attributable to non-controlling interestsComprehensive income (loss) attributable to non-controlling interests(41,263)(70,145)(54,624)(93,978)
Comprehensive income (loss) attributable to GoHealth, Inc.Comprehensive income (loss) attributable to GoHealth, Inc.$(28,925)$(43,952)$(38,102)$(57,477)
Comprehensive income (loss) attributable to GoHealth, Inc.
Comprehensive income (loss) attributable to GoHealth, Inc.
The accompanying Notes are an integral part of these Condensed Consolidated Financial Statements.
GoHealth, Inc.20232024 Form 10-Q  5


GOHEALTH, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except per share amounts, unaudited)

Jun. 30, 2023Dec. 31, 2022
Mar. 31, 2024Mar. 31, 2024Dec. 31, 2023
AssetsAssets
Current assets:Current assets:
Current assets:
Current assets:
Cash and cash equivalentsCash and cash equivalents$25,364 $16,464 
Accounts receivable, net of allowance for doubtful accounts of $734 in 2023 and $89 in 202235,984 4,703 
Cash and cash equivalents
Cash and cash equivalents
Accounts receivable, net of allowance for doubtful accounts of $6 in 2024 and $27 in 2023
Commissions receivable - currentCommissions receivable - current294,319 335,796 
Prepaid expense and other current assetsPrepaid expense and other current assets12,431 57,593 
Total current assetsTotal current assets368,098 414,556 
Commissions receivable - non-currentCommissions receivable - non-current617,243 695,637 
Operating lease ROU assetOperating lease ROU asset17,215 21,483 
Other long-term assetsOther long-term assets2,243 1,721 
Property, equipment, and capitalized software, netProperty, equipment, and capitalized software, net23,870 25,282 
Intangible assets, netIntangible assets, net453,583 500,611 
Total assetsTotal assets$1,482,252 $1,659,290 
Liabilities, Redeemable Convertible Preferred Stock and Stockholders’ EquityLiabilities, Redeemable Convertible Preferred Stock and Stockholders’ Equity
Current liabilities:Current liabilities:
Current liabilities:
Current liabilities:
Accounts payable
Accounts payable
Accounts payableAccounts payable$8,704 $15,148 
Accrued liabilitiesAccrued liabilities49,802 53,334 
Commissions payable - currentCommissions payable - current103,953 122,023 
Short-term operating lease liabilityShort-term operating lease liability6,765 8,974 
Deferred revenueDeferred revenue27,721 50,594 
Current portion of long-term debtCurrent portion of long-term debt— 5,270 
Other current liabilitiesOther current liabilities13,313 10,112 
Total current liabilitiesTotal current liabilities210,258 265,455 
Non-current liabilities:Non-current liabilities:
Commissions payable - non-currentCommissions payable - non-current220,652 253,118 
Commissions payable - non-current
Commissions payable - non-current
Long-term operating lease liabilityLong-term operating lease liability35,234 38,367 
Long-term debt, net of current portionLong-term debt, net of current portion496,224 504,810 
Other non-current liabilitiesOther non-current liabilities9,823 5,839 
Total non-current liabilitiesTotal non-current liabilities761,933 802,134 
Commitments and Contingencies (Note 11)Commitments and Contingencies (Note 11)Commitments and Contingencies (Note 11)
Series A redeemable convertible preferred stock — $0.0001 par value; 50 shares authorized; 50 shares issued and outstanding at June 30, 2023 and December 31, 2022. Liquidation preference of $50.9 million at June 30, 2023 and December 31, 2022.49,302 49,302 
Series A redeemable convertible preferred stock — $0.0001 par value; 50 shares authorized; 50 shares issued and outstanding as of both March 31, 2024 and December 31, 2023. Liquidation preference of $51.9 million and $50.9 million as of March 31, 2024 and December 31, 2023, respectively.
Stockholders’ equity:Stockholders’ equity:
Class A common stock – $0.0001 par value; 1,100,000 shares authorized; 9,499 and 8,963 shares issued; 9,418 and 8,950 shares outstanding at June 30, 2023 and December 31, 2022, respectively.
Class B common stock – $0.0001 par value; 616,022 and 616,259 shares authorized; 12,818 and 13,054 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively.
Preferred stock – $0.0001 par value; 20,000 shares authorized (including 50 shares of Series A redeemable convertible preferred stock authorized and 200 shares of Series A-1 convertible preferred stock authorized); 50 shares issued and outstanding at June 30, 2023 and December 31, 2022.— — 
Series A-1 convertible preferred stock— $0.0001 par value; 200 shares authorized; no shares issued and outstanding at June 30, 2023 and December 31, 2022.— — 
Treasury stock – at cost; 81 and 13 shares of Class A common stock at June 30, 2023 and December 31, 2022, respectively.(1,051)(345)
Class A common stock – $0.0001 par value; 1,100,000 shares authorized; 10,160 and 9,823 shares issued; 9,898 and 9,651 shares outstanding as of March 31, 2024 and December 31, 2023, respectively.
Class A common stock – $0.0001 par value; 1,100,000 shares authorized; 10,160 and 9,823 shares issued; 9,898 and 9,651 shares outstanding as of March 31, 2024 and December 31, 2023, respectively.
Class A common stock – $0.0001 par value; 1,100,000 shares authorized; 10,160 and 9,823 shares issued; 9,898 and 9,651 shares outstanding as of March 31, 2024 and December 31, 2023, respectively.
Class B common stock – $0.0001 par value; 615,987 and 616,018 shares authorized; 12,783 and 12,814 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively.
Preferred stock – $0.0001 par value; 20,000 shares authorized (including 50 shares of Series A redeemable convertible preferred stock authorized and 200 shares of Series A-1 convertible preferred stock authorized); 50 shares issued and outstanding as of both March 31, 2024 and December 31, 2023.
Series A-1 convertible preferred stock— $0.0001 par value; 200 shares authorized; no shares issued and outstanding as of both March 31, 2024 and December 31, 2023.
Treasury stock – at cost; 262 and 173 shares of Class A common stock as of March 31, 2024 and December 31, 2023, respectively.
Additional paid-in capitalAdditional paid-in capital646,232 626,269 
Accumulated other comprehensive income (loss)Accumulated other comprehensive income (loss)(125)(144)
Accumulated deficitAccumulated deficit(395,144)(357,023)
Total stockholders’ equity attributable to GoHealth, Inc.Total stockholders’ equity attributable to GoHealth, Inc.249,914 268,759 
Non-controlling interestsNon-controlling interests210,845 273,640 
Total stockholders’ equityTotal stockholders’ equity460,759 542,399 
Total liabilities, redeemable convertible preferred stock and stockholders’ equityTotal liabilities, redeemable convertible preferred stock and stockholders’ equity$1,482,252 $1,659,290 
The accompanying Notes are an integral part of these Condensed Consolidated Financial Statements.
GoHealth, Inc.20232024 Form 10-Q  6


GOHEALTH, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY
(in thousands, unaudited)
Three months ended Jun. 30, 2023
Class A Common StockClass B Common StockTreasury Stock
SharesAmountSharesAmountSharesAmountAdditional Paid-In CapitalAccumulated DeficitAccumulated Other Comprehensive Income (Loss)Non-Controlling InterestStockholders’ Equity
Balance at Apr. 1, 20239,002 $1 13,052 $1 (20)$(459)$630,316 $(366,202)$(142)$259,784 $523,299 
Three months ended Mar. 31, 2024Three months ended Mar. 31, 2024
Class A Common Stock
Shares
Shares
SharesAmountSharesAmountSharesAmountAdditional Paid-In CapitalAccumulated DeficitAccumulated Other Comprehensive Income (Loss)Non-Controlling InterestStockholders’ Equity
Balance at Jan. 1, 2024
Net income (loss)Net income (loss)(28,942)(41,287)(70,229)
Issuance of Class A common shares related to share-based compensation plansIssuance of Class A common shares related to share-based compensation plans264 — 450 450 
Share-based compensation expenseShare-based compensation expense8,681 8,681 
Foreign currency translation adjustmentsForeign currency translation adjustments17 24 41 
Class A common shares repurchased for employee tax withholdingsClass A common shares repurchased for employee tax withholdings(61)(592)(592)
Dividends accumulated on Series A redeemable convertible preferred stockDividends accumulated on Series A redeemable convertible preferred stock(891)— (891)
Forfeitures of Time-Vesting UnitsForfeitures of Time-Vesting Units(1)— — 
Redemption of LLC InterestsRedemption of LLC Interests233 — (233)— 7,676 (7,676)— 
Balance at Jun. 30, 20239,499 $1 12,818 $1 (81)$(1,051)$646,232 $(395,144)$(125)$210,845 $460,759 
Balance at Mar. 31, 2024
Three months ended Jun. 30, 2022
Class A Common StockClass B Common StockTreasury Stock
SharesAmountSharesAmountSharesAmountAdditional Paid-In CapitalAccumulated DeficitAccumulated Other Comprehensive Income (Loss)Non-Controlling InterestStockholders’ Equity
Balance at Apr. 1, 20228,129 $1 13,289 $1 (11)$(329)$583,323 $(221,800)$(101)$498,833 $859,958 
Net income (loss)(43,819)(69,933)(113,752)
Issuance of Class A common shares related to share-based compensation plans562 — 337 337 
Share-based compensation expense12,138 12,138 
Foreign currency translation adjustments(133)(212)(345)
Class A common shares repurchased for employee tax withholdings(1)(15)(15)
Dividends accumulated on Series A redeemable convertible preferred stock— — 
Forfeitures of Time-Vesting Units(12)— — 
Redemption of LLC Interests106 — (106)— 16,830 (16,830)— 
Balance at Jun. 30, 20228,797 $1 13,171 $1 (12)$(344)612,628 $(265,619)$(234)$411,858 $758,321 

Three months ended Mar. 31, 2023
Class A Common StockClass B Common StockTreasury Stock
SharesAmountSharesAmountSharesAmountAdditional Paid-In CapitalAccumulated DeficitAccumulated Other Comprehensive Income (Loss)Non-Controlling InterestStockholders’ Equity
Balance at Jan. 1, 20238,963 $1 13,054 $1 (13)$(345)$626,269 $(357,023)$(144)$273,640 $542,399 
Net income (loss)(9,179)(13,364)(22,543)
Issuance of Class A common shares related to share-based compensation plans38 — — — 
Share-based compensation expense4,444 4,444 
Foreign currency translation adjustments
Class A common shares repurchased for employee tax withholdings(7)(114)(114)
Dividends accumulated on Series A redeemable convertible preferred stock(892)(892)
Forfeitures of Time-Vesting Units(1)— — 
Redemption of LLC Interests— (1)— 495 (495)— 
Balance at Mar. 31, 20239,002 $1 13,052 $1 (20)$(459)630,316 $(366,202)$(142)$259,784 $523,299 

The accompanying Notes are an integral part of these Condensed Consolidated Financial Statements.
GoHealth, Inc.20232024 Form 10-Q  7


GOHEALTH, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY
(in thousands, unaudited)
Six months ended Jun. 30, 2023
Class A Common StockClass B Common StockTreasury Stock
SharesAmountSharesAmountSharesAmountAdditional Paid-In CapitalAccumulated DeficitAccumulated Other Comprehensive Income (Loss)Non-Controlling InterestStockholders’ Equity
Balance at Jan. 1, 20238,963 $1 13,054 $1 (13)$(345)$626,269 $(357,023)$(144)$273,640 $542,399 
Net income (loss)(38,121)(54,651)(92,772)
Issuance of Class A common shares related to share-based compensation plans302 — 450 450 
Share-based compensation expense13,125 13,125 
Foreign currency translation adjustments19 27 46 
Class A common shares repurchased for employee tax withholdings(68)(706)— (706)
Dividends accumulated on Series A redeemable convertible preferred stock(1,783)(1,783)
Forfeitures of Time-Vesting Units(2)$ $ 
Redemption of LLC Interests234 $ (234)$ $8,171 $(8,171)$ 
Balance at Jun. 30, 20239,499 $1 12,818 $1 (81)$(1,051)$646,232 $(395,144)$(125)$210,845 $460,759 
Six months ended Jun. 30, 2022
Class A Common StockClass B Common StockTreasury Stock
SharesAmountSharesAmountSharesAmountAdditional Paid-In CapitalAccumulated DeficitAccumulated Other Comprehensive Income (Loss)Non-Controlling InterestStockholders’ Equity
Balance at Jan. 1, 20227,699 $1 13,690 $1  $ $561,447 $(208,317)$(59)$539,387 $892,490 
Net income (loss)(57,302)(93,691)(150,993)
Issuance of Class A common shares related to share-based compensation plans596 — 337 337 
Share-based compensation expense17,293 17,293 
Foreign currency translation adjustments(175)(287)(462)
Class A common shares repurchased for employee tax withholdings(12)(344)(344)
Dividends accumulated on Series A redeemable convertible preferred stock— 
Forfeitures of Time-Vesting Units(17)$ $ 
Redemption of LLC Interests502 $ (502)$ $33,551 $(33,551)$ 
Balance at Jun. 30, 20228,797 $1 13,171 $1 $ (12)$(344)$612,628 $(265,619)$(234)$411,858 $758,321 

The accompanying Notes are an integral part of these Condensed Consolidated Financial Statements.
GoHealth, Inc.2023 Form 10-Q  8


GOHEALTH, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands, unaudited)
Six months ended Jun. 30,
20232022
Three months ended Mar. 31,Three months ended Mar. 31,
202420242023
Operating ActivitiesOperating Activities
Net income (loss)Net income (loss)$(92,772)$(150,993)
Net income (loss)
Net income (loss)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Share-based compensation
Share-based compensation
Share-based compensationShare-based compensation13,125 17,293 
Depreciation and amortizationDepreciation and amortization5,606 5,330 
Amortization of intangible assetsAmortization of intangible assets47,029 47,029 
Amortization of debt discount and issuance costsAmortization of debt discount and issuance costs1,664 1,381 
Operating lease impairment charges2,687 24,995 
Non-cash lease expense
Non-cash lease expense
Non-cash lease expenseNon-cash lease expense2,063 2,862 
Other non-cash itemsOther non-cash items(191)29 
Changes in assets and liabilities:Changes in assets and liabilities:
Changes in assets and liabilities:
Changes in assets and liabilities:
Accounts receivable
Accounts receivable
Accounts receivableAccounts receivable(31,057)(21,119)
Commissions receivableCommissions receivable119,838 101,928 
Prepaid expenses and other assetsPrepaid expenses and other assets44,521 39,795 
Accounts payableAccounts payable(6,460)(25,885)
Accrued liabilitiesAccrued liabilities(3,531)(19,898)
Deferred revenueDeferred revenue(22,873)2,155 
Commissions payableCommissions payable(50,535)(26,279)
Operating lease liabilitiesOperating lease liabilities(5,341)(2,993)
Other liabilitiesOther liabilities7,567 10,747 
Net cash provided by (used in) operating activitiesNet cash provided by (used in) operating activities31,340 6,377 
Investing ActivitiesInvesting Activities
Purchases of property, equipment and software
Purchases of property, equipment and software
Purchases of property, equipment and softwarePurchases of property, equipment and software(4,660)(9,658)
Net cash provided by (used in) investing activitiesNet cash provided by (used in) investing activities(4,660)(9,658)
Financing ActivitiesFinancing Activities
Proceeds from stock option exercises65 — 
Repayment of borrowingsRepayment of borrowings(15,402)(2,635)
Repayment of borrowings
Repayment of borrowings
Payment of preferred stock dividends
Repurchase of shares to satisfy employee tax withholding obligations
Payment of preferred stock dividends(1,783)— 
Repurchase of shares to satisfy employee tax withholding obligations(706)— 
Debt issuance cost payments— (1,725)
Principal payments under capital lease obligations— (103)
Net cash provided by (used in) financing activities
Net cash provided by (used in) financing activities
Net cash provided by (used in) financing activitiesNet cash provided by (used in) financing activities(17,826)(4,463)
Effect of exchange rate changes on cash and cash equivalentsEffect of exchange rate changes on cash and cash equivalents46 (461)
Increase (decrease) in cash and cash equivalentsIncrease (decrease) in cash and cash equivalents8,900 (8,205)
Cash and cash equivalents at beginning of periodCash and cash equivalents at beginning of period16,464 84,361 
Cash and cash equivalents at end of periodCash and cash equivalents at end of period$25,364 $76,156 
Supplemental Disclosure of Cash Flow InformationSupplemental Disclosure of Cash Flow Information
Non-cash investing and financing activities:Non-cash investing and financing activities:
Non-cash investing and financing activities:
Non-cash investing and financing activities:
Purchases of property, equipment and software included in accounts payablePurchases of property, equipment and software included in accounts payable$16 $683 
Purchases of property, equipment and software included in accounts payable
Purchases of property, equipment and software included in accounts payable
The accompanying Notes are an integral part of these Condensed Consolidated Financial Statements.
GoHealth, Inc.20232024 Form 10-Q  98


GOHEALTH, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(In thousands, except per share amounts, unaudited)
1. DESCRIPTION OF BUSINESS AND SIGNIFICANT ACCOUNTING POLICIES
Description of Business

GoHealth Inc. (the “Company”) is a leading health insurance marketplace and Medicare-focused digital health company whose missionpurpose is to improvecompassionately ensure consumers’ peace of mind when making healthcare decisions so they can focus on living life. With a widely scalable end-to-end platform and substantial presence in America. The Company works withthe Medicare landscape, we believe we are uniquely positioned as a trusted partner to the 65 million Medicare-eligible Americans, as well as the 11,000 Americans becoming eligible each day, as they navigate one of life's most important purchasing decisions. For many of these consumers, enrolling in a health insurance plan is confusing and difficult, and seemingly small differences between health plans may lead to significant out-of-pocket costs or lack of access to critical providers and medicines. We aim to simplify the process by offering education, comparison guidance, transparency and choice. This includes providing a large selection of leading health plan partnerschoices, advice informed by consumers’ specific needs, transparency of health plan benefits and fit, assistance accessing available government subsidies and a high-touch consumer care team. We partner with health plans across the nation that provide access to provide solutionshigh quality health plans across all 50 states.
We primarily offer Medicare plans, including, but not limited to, efficiently enroll individuals in health insuranceMedicare Advantage, Medicare Supplement and prescription drug plans. The Company’sOur proprietary technology platform leverages modern machine-learning algorithms, powered by over two decades of insurance purchasing behavior, to reimagine the optimal process for helping individuals find the bestof matching a health insurance plan for theirto a consumer’s specific needs. The Company’s differentiated combination of a vertically integrated consumer acquisition platform andOur unbiased, technology-driven marketplace coupled with highly skilled and trainedlicensed agents has enabledfacilitated the Company to enrollenrollment of millions of peopleconsumers in Medicare and individual and family plans since GoHealth’s inception. CertainHealth plan partners benefit from our platform by gaining access to the large and rapidly growing Medicare-eligible population. We believe health plan partners utilize our large-scale data, technology and efficient marketing processes to maximize scale and reduce their cost of the Company’s operations do business as GoHealth, LLC,submission, compared to health plan partner-employed agent workforces.
We believe our streamlined, consumer-centric Encompass operating model drives both high quality enrollments and a controlled subsidiary of the Company that was founded in 2008.
The Company was incorporated in Delaware on March 27, 2020,strong consumer experience. Our consumer-centric approach positions us to be a trusted, high-quality enrollment partner for the purpose of facilitating an initial public offering (the “IPO”)both consumers and other related transactions in order to carry on the business of GoHealth Holdings, LLC, a Delaware limited liability company, and its controlled subsidiaries (collectively, "GHH, LLC"). Following the IPO and pursuant to a reorganization into a holding company structure, the Company is a holding company and its principal asset is a controlling equity interest in GHH, LLC. As the sole managing member of GHH, LLC, the Company operates and controls all of the business and affairs of GHH, LLC, and through GHH, LLC and its subsidiaries, conducts its business.health plan partners.
Basis of Presentation and Significant Accounting Policies
In connection withThe Company was incorporated in Delaware on March 27, 2020 for the purpose of facilitating an initial public offering (the “IPO”) and other related transactions in order to carry on the business of GHH, LLC, a Delaware limited liability company, and its controlled subsidiaries (collectively, “GHH, LLC”). Following the IPO and pursuant to a reorganization into a holding company structure, the Company becameis a holding company and its principal asset is a controlling equity interest in GHH, LLC. As the sole managing member of GHH, LLC, the Company operates and controls all of the managementbusiness and affairs of GHH, LLC.LLC, and through GHH, LLC and its subsidiaries, conducts its business. As a result, the Company consolidates GHH, LLC’s financial results in its Condensed Consolidated Financial Statements and reports a non-controlling interestinterests for the economic interest in GHH, LLC held by the Continuing Equity Owners. Substantially concurrently with the consummation of the IPO, the existing limited liability company agreement of GHH, LLC was amended and restated to, among other things, recapitalize its capital structure by creating a single new class of units (the “common units”) and provide for a right of redemption of common units (subject in certain circumstances to time-based vesting requirements and certain other restrictions) in exchange for, at the Company’s election, cash or newly-issued shares of Class A common stock on a one-for-one basis. In connection with any redemption, the Company will receive a corresponding number of common units, increasing the Company’s total ownership interest in GHH, LLC.
Net income and loss is allocated to the Continuing Equity Owners on a pro-rata basis, assuming that any Class B common units that are subject to time-based vesting requirements are fully vested.
GHH, LLC is a holding company with no operating assets or operations and was formed to acquire a 100% equity interest in Norvax. On May 6, 2020, Blizzard Parent, LLC changed its name to “GoHealth Holdings, LLC.” GHH, LLC owns 100% of Blizzard Midco, LLC, which owns 100% of Norvax. For all of the periods reported in these Condensed Consolidated Financial Statements, GHH, LLC has not and does not have any material operations on a standalone basis, and all of the operations of GHH, LLC are carried out by Norvax.
The accompanying Condensed Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”)GAAP for interim financial information, but do not include all information and footnote disclosures required under GAAP for annual financial statements. The accompanying Condensed Consolidated Financial Statements and related notes should be read in conjunction with the audited Consolidated Financial Statements and related notes included in ourthe Company’s 2023 Annual Report on Form 10-K, for the year ended December 31, 2022, which was filed with the Securities and Exchange Commission on March 23, 2023.14, 2024. In the opinion of management, the interim Condensed Consolidated Financial Statements include all adjustments, consisting only of normal recurring adjustments, necessary for the fair presentation of the Company’s financial position, results of operations and cash flows as of the dates and for the periods presented. All intercompany transactions and balances are eliminated in consolidation. Certain prior period amounts have been reclassified to conform with the current period presentation. During the first quarter of 2023, the Company reorganized its operating
“Consumer care and reportable segments into a single operating and reportable segment. Refer to the “Segment Information” section within this Note below for further information regarding this update. The Company also changed the presentation of its disaggregation of revenue table, which is further described in Note 9. “Revenue” of the Notes to Condensed Consolidated Financial Statements. These reclassifications had no impact on the Company’s financial position, results of operations or cash flows. All share and per share amounts have been retroactively adjusted to reflect the one-for-fifteen reverse stock split. See Note 5. “Stockholders' Equity” of the Notes to Condensed Consolidated Financial Statements for more information. Revenue shareenrollment” on the Condensed Consolidated StatementStatements of Operations, previously referred to as “cost of revenue”“customer care and enrollment” reflects a name change only and does not require any financial information to be reclassified from previous periods.
There have been no material changes to the Company’s significant accounting policies from those disclosed in the notes to the Company’s audited Consolidated Financial Statements as
GoHealth, Inc.2023 Form 10-Q  10


of and for the year ended December 31, 2022,2023, which were included in ourthe Company’s 2023 Annual Report on Form 10-K for the fiscal year ended December 31, 2022.10-K.
Use of Estimates
GoHealth, Inc.2024 Form 10-Q  9


The preparation of the Condensed Consolidated Financial Statements in conformity with GAAP requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities at the date of the Condensed Consolidated Financial Statements and the reported amounts of revenues and expenses during the reporting periods. The Company bases its estimates on historical experience and on various other assumptions that management believes are reasonable under the circumstances, the results of which form the basis for making judgments about carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.
Seasonality
The Medicare annual enrollment period (“AEP”) occurs from October 15th to December 7th. As a result, and in general, we experience an increase in the number of Submissions during the fourth quarter and an increase in expense related to the Medicare Submissions during the third and fourth quarters. Additionally, as a result of the annual Medicare Advantage open enrollment period that occurs from January 1st to March 31st, Medicare Submissions are typically second highestsecond-highest in our first quarter. The second and third quarters are known as special election periods, andduring which Medicare Submissions are our seasonally smallest quarters.typically lowest. A significant portion of our marketing and advertising expenses is driven by the number of health insurance applications submitted through us. Marketing and advertising expenses are generally higher in the fourth quarter during the Medicare annual enrollment period,AEP, but because commissions from approved customersconsumers are paid to us over time, our operating cash flows could be adversely impacted by a substantial increase in marketing and advertising expenses as a result of a higher volume of applications submittedSubmissions during the fourth quarter or positively impacted by a substantial decline in marketing and advertising expenses as a result of lower volume of applications submittedSubmissions during the fourth quarter.
Segment Information
Operating segments are identified as components of an enterprise about which separate discrete financial information is available and reviewed regularly by the chief operating decision-maker (“CODM”). The Company’s CODM is its chief executive officerChief Executive Officer who reviews financial information together with certain operating metrics principally to make decisions about how to allocate resources and to measure the Company’s performance. During the first quarter of 2023, theThe Company reorganized its operations from four operating and reportable segments tohas one operating and reportable segment. The change reflects how the CODM evaluates the Company’s operating and financial performance on a consolidated basis and is consistent with changes made to the Company’s internal reporting structure. Additionally, the single operating segment aligns with the Company’s shift in focus towards Medicare products. All prior period comparative segment information was recast to reflect the current single operating segment in accordance with Accounting Standards Codification (“ASC”) 280, Segment Reporting.
Recent Accounting Pronouncements
In March 2020November 2023, the Financial Accounting Standards Board (the “FASB”) issued ASU No. 2020-04,2023-07, Reference Rate Reform Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures(“ASC 848”). The purpose of ASC 848 is to provide optional guidance to ease the potential effects on financial reporting of the market-wide migration away from Interbank Offered Rates to alternative reference rates. ASC 848 applies only to contracts, hedging relationships and other transactions that reference a reference rate expected to be discontinued because of reference rate reform. The new guidance allows entities to prospectively account for contract modifications within the scope of ASC 848. Therefore, such modifications will not require entities to remeasure the modified contract at the modification date or to reassess a prior accounting conclusion. The guidance may be applied upon issuance of ASC 848 through December 31, 2024, as amended by (“ASU 2022-06, Reference Rate Reform (ASC 848): Deferral of the Sunset Date of Topic 8482023-07”), which extendedaims to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The amendments in ASU 2023-07 do not change how a public entity identifies its operating segments, aggregates those operating segments or applies the final sunset date fromquantitative thresholds to determine its reportable segments. ASU 2023-07 is effective for fiscal years beginning after December 31, 202215, 2023, and for interim periods beginning after December 15, 2024, with early adoption permitted. The Company is currently assessing the impact on our related disclosures.
In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures ("ASU 2023-09"). ASU 2023-09 enhanced annual disclosures regarding the income tax rate reconciliation and income taxes paid information. For public business entities, ASU 2023-09 is effective for annual periods beginning after December 31,15, 2024. The Company adopted ASC 848 on March 15, 2023 upon entry into Amendment No. 10 tois currently assessing the Company’s Credit Agreement, as further discussed in Note 4, “Long-Term Debt” of these Notes to Condensed Consolidated Financial Statements. The adoption of this standard did not have an impact on the Condensed Consolidated Financial Statements andour related disclosures.
2. FAIR VALUE MEASUREMENTS

The Company defines fair value as the price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques the Company uses to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs. The Company classifieshas applied the inputs used to measureprovisions of fair value intoaccounting for purposes of computing the following hierarchy:
fair value of financial instruments for disclosure purposes as presented below.
GoHealth, Inc.2023 Form 10-Q  11


Level 1 InputsUnadjusted quoted prices in active markets for identical assets or liabilities.
Level 2 InputsUnadjusted quoted prices in active markets for similar assets or liabilities; unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability.
Level 3 InputsUnobservable inputs for the asset or liability.
Fair Value Measurements
The carrying amount of certain financial instruments, including cash and cash equivalents, accounts receivable, unbilled receivables, accounts payable and accrued expenses approximate fair value due to the short maturity of these instruments. The carrying value of debt approximates fair value due to the variable nature of interest rates.
GoHealth, Inc.2024 Form 10-Q  10


As part of the Company’s continued cost savings initiatives, the Company is actively looking to terminate or sublease certain office spaces and call centers. These actions resulted in a $2.7 million operating lease impairment charge for bothcharges of $2.7 million during the three and six months ended June 30, 2023 and a $25.0 millionsecond fiscal quarter of 2023. The Company recorded no operating lease impairment chargecharges for both the three and six months ended June 30, 2022.

March 31, 2024 and 2023. The Company continues to evaluate its portfolio of properties, and thus it is possible that impairments could be identified in future periods, and such amounts could be material. The operating lease impairment charges reduce the carrying value of the associated right-of-use (“ROU”) assets and leasehold improvements to the estimated fair values. The fair values are estimated using a discounted cash flows approach based on forecasted future cash flows expected to be derived from the property based on current sublease market rent, which is considered a level 3 input in the fair value hierarchy, and other key assumptions such as future sublease market conditions and the discount rate.
During the twelve months ended December 31, 2023, the Company recorded indefinite-lived trade names impairment charges of $10.0 million. The Company recorded no indefinite-lived trade names impairment charges for the three months ended March 31, 2024 and 2023. Determination of the fair value of the indefinite-lived trade names involves estimates and assumptions which are considered a level 3 input in the fair value hierarchy. For more information, refer to Note 3 “Intangible Assets, Net.”
3. INTANGIBLE ASSETS, NET
Intangible Assets
Fourth Quarter 2023 Indefinite-Lived Intangible Asset Impairment Charges
In connection with its annual indefinite-lived impairment test performed as of November 30, 2023, the Company determined that the fair value of its indefinite-lived trade names no longer exceeded their carrying value. As a result, during the twelve months ended December 31, 2023, the Company recorded indefinite-lived trade names impairment charges of $10.0 million to write down the carrying value of the indefinite-lived trade names to their fair value of $73.0 million. Determination of fair value involves utilizing the relief-from-royalty under the income approach which contains significant estimates and assumptions including, among others, revenue projections as well as selecting appropriate royalty and discount rates, which are considered level 3 inputs in the fair value hierarchy. The indefinite-lived trade names impairment charge was a result of an increase in the discount rate driven by changes in forecast assumptions from the prior year. While the Company believes the judgments and assumptions are reasonable, different assumptions could change the estimated fair value and, therefore, additional impairments could be required. Weakening industry or economic trends, disruptions to the Company's business, changes in discount rate assumptions, unexpected significant changes or planned changes in the use of the assets or in the Company’s entity structure are all factors which may adversely impact the assumptions used in the valuation.
There was no impairment of intangible assets for the three months ended March 31, 2024 and 2023.
The gross carrying amounts, accumulated amortization and net carrying amounts of the Company’s definite-lived amortizable intangible assets, as well as its indefinite-lived intangible trade names, are as follows:
Jun. 30, 2023
Mar. 31, 2024Mar. 31, 2024
(in thousands)(in thousands)Gross Carrying AmountAccumulated AmortizationNet Carrying Amount(in thousands)Gross Carrying AmountAccumulated AmortizationNet Carrying Amount
Developed technologyDeveloped technology$496,000 $269,257 $226,743 
Customer relationshipsCustomer relationships232,000 88,160 143,840 
Total intangible assets subject to amortizationTotal intangible assets subject to amortization$728,000 $357,417 $370,583 
Indefinite-lived trade namesIndefinite-lived trade names83,000 
Total intangible assetsTotal intangible assets$453,583 
Dec. 31, 2022
Dec. 31, 2023Dec. 31, 2023
(in thousands)(in thousands)Gross Carrying AmountAccumulated AmortizationNet Carrying Amount(in thousands)Gross Carrying AmountAccumulated AmortizationNet Carrying Amount
Developed technologyDeveloped technology$496,000 $233,829 $262,171 
Customer relationshipsCustomer relationships232,000 76,560 155,440 
Total intangible assets subject to amortizationTotal intangible assets subject to amortization$728,000 $310,389 $417,611 
Indefinite-lived trade namesIndefinite-lived trade names83,000 
Total intangible assetsTotal intangible assets$500,611 
There was no impairment of intangible assets for the three and six months ended June 30, 2023 and 2022.
As of June 30, 2023,March 31, 2024, expected amortization expense related to intangible assets for each of the five succeeding years is as follows:
GoHealth, Inc.20232024 Form 10-Q  1211


(in thousands)(in thousands)Developed TechnologyCustomer RelationshipsTotal
Remainder of 2023$35,429 $11,600 $47,029 
202470,857 23,200 94,057 
(in thousands)
(in thousands)
Remainder of 2024
Remainder of 2024
Remainder of 2024
2025
2025
2025202570,857 23,200 94,057 
2026202649,600 23,200 72,800 
2026
2026
20272027— 23,200 23,200 
2027
2027
2028
2028
2028
Thereafter
Thereafter
ThereafterThereafter— 39,440 39,440 
TotalTotal$226,743 $143,840 $370,583 
Total
Total
4. LONG-TERM DEBT
The Company’s long-term debt consisted of the following:
(in thousands)(in thousands)Jun. 30, 2023Dec. 31, 2022(in thousands)Mar. 31, 2024Dec. 31, 2023
Term Loan FacilitiesTerm Loan Facilities$502,796 $518,133 
Less: Unamortized debt discount and issuance costsLess: Unamortized debt discount and issuance costs(6,572)(8,053)
Less: Unamortized debt discount and issuance costs
Less: Unamortized debt discount and issuance costs
Total debtTotal debt$496,224 $510,080 
Less: Current portion of long-term debtLess: Current portion of long-term debt— (5,270)
Total long-term debtTotal long-term debt$496,224 $504,810 
Maturities of long-term debt for each of the next five years is as follows:
(in thousands)
Remainder of 2024$75,000 
2025427,796 
2026— 
2027— 
2028— 
Thereafter— 
Total$502,796 
Term Loan Facilities
On September 13,During 2019, Norvax (the “Borrower”) entered into a first lien credit agreement (the(as amended from time to time, the “Credit Agreement”) which provided for a $300.0 million aggregate principal amount senior secured term loan facility (the “Initial Term Loan Facility”). During 2020 and 2021, the Company entered into a series of amendments to the Credit Agreement to provide for, among other items as further described below, (i) $117.0 million of incremental term loans (the “Incremental Term Loan Facility”), (ii) a new class of incremental term loans (the ”2021“2021 Incremental Term Loans”) in an aggregate principal amount equal to $310.0 million which was used to refinance $295.5 million of outstanding principal under the Initial Term Loan Facility, and (iii) a new class of incremental term loans (the “2021-2 Incremental Term Loans”) in an aggregate principal amount equal to $100.0 million.
On March 14, 2022, the Company entered into Amendment No. 7 to the Credit Agreement and Incremental Facility Agreement (“Amendment No. 7”). Amendment No. 7 provided that (a) the 2021 Incremental Term Loans, from and after the Amendment No. 7 Effective Date, will bear interest at either (i) alternate base rate (“ABR”) plus 5.50% per annum or (ii) LIBOR plus 6.50% per annum and (b) the 2021-2 Incremental Term Loans, from and after the Amendment No. 7 Effective Date, will bear interest at either (i) ABR plus 5.50% per annum or (ii) LIBOR plus 6.50% per annum. Amendment No. 7 further amended the Credit Agreement to remove testing of the Net Leverage Ratio for the December 31, 2021 period and increased the maximum permitted Net Leverage Ratio for future reporting periods through March 31, 2023. The Company incurred $1.7 million of debt issuance costs associated with Amendment No. 7, which are being amortized over the life of the debt to interest expense using the effective interest method.
On August 12, 2022, the Company entered into Amendment No. 8 to the Credit Agreement and Incremental Facility Agreement (“Amendment No. 8”). Amendment No. 8 provided that (a) the 2021 Incremental Term Loans, from and after the Amendment No. 8 Effective Date, will bear interest at either (i) ABR plus 6.50% per annum or (ii) LIBOR plus 7.50% per annum and (b) the 2021-2 Incremental Term Loans, from and after the Amendment No. 8 Effective Date, will bear interest at either (i) ABR plus 6.50% per annum or (ii) LIBOR plus 7.50% per annum. Amendment No. 8 further amended the Credit Agreement to increase the maximum permitted Net Leverage Ratio for future reporting periods from December 31, 2022 through June 30, 2023. The Company incurred $1.0 million of debt issuance costs associated with Amendment No. 8, which are being amortized over the life of the debt to interest expense using the effective interest method.
On November 9, 2022, the Company entered into Amendment No. 9 to the Credit Agreement (“Amendment No. 9”). Amendment No. 9 provided that the Incremental Term Loan, from and after the Amendment No. 8 Effective Date, will bear interest at either (i) ABR plus 6.50% per annum or (ii) LIBOR plus 7.50% per annum. Amendment No. 9 further amended the Credit Agreement to increase the maximum permitted Net Leverage Ratio for the September 30, 2023 reporting period.
On March 15, 2023, the Company entered into Amendment No. 10 to the Credit Agreement (“Amendment No. 10”). Amendment No. 10 amended the Credit Agreement to convert the existing London Interbank-Offered Rate (“LIBOR”)-based rate applicable to the term loan and revolving credit facilities under the Credit Agreement to a Term Secured Overnight Financing Rate (“SOFR”) with a credit spread adjustment of 0.10%, 0.15% or 0.25% per annum for interest periods of one month, three months, or six months, respectively, and a floor of 1.00%, effective on the amendment date. Amendment No. 10 provided that the Incremental Term Loan, the 2021 Incremental Term Loans, and the 2021-2 Incremental Term Loans from and after the rate set date following the Amendment No. 10 Effective Date, will bear interest at either (i) ABR plus 6.50% per annum or (ii) SOFR plus 7.50% per annum.
GoHealth, Inc.2023 Form 10-Q  13


The Company collectively refers to the Initial Term Loan Facility, the Incremental Term Loan Facility, the 2021 Incremental Term Loans and the 2021-2 Incremental Term Loans as the “Term Loan Facilities”Facilities.”
The Term Loan Facilities all bear interest at either (i) ABR plus 6.5% per annum or (ii) SOFR plus 7.5% per annum. Per Amendment No. 11 to the Credit Agreement (“Amendment No. 11”), as further described below, after August 31, 2024 the Term Loan Facilities all bear interest at either ABR plus 7.0% or SOFR plus 8.0%.

On March 12, 2024, the Borrower entered into Amendment No. 11. Prior to Amendment No. 11, the Revolving Credit Facilities (as defined below) were separated into two classes of revolving commitments consisting of Class A Revolving Commitments in the amount of $30.0 million (the “Class A Revolving Commitments”) and Class B Revolving Commitments in the amount of $170.0 million (the “Class B Revolving Commitments”), each maturing on September 13, 2024. In connection with Amendment No. 11, each existing lender under the Class A Revolving Commitments and the Class B Revolving Commitments received the option to extend the maturity of their respective commitments through June 30, 2025. Under the terms of Amendment No. 11, the lenders consenting to the extension formed a new tranche of Class A Revolving Commitments (the “New Class A Revolving Commitments”) and the non-consenting lenders remain part of the existing Class B Revolving Commitments (the “Remaining Class B Revolving Commitments”). Each consenting lender received a 50.0% commitment reduction, resulting in a total of $88.5 million available to the Borrower under the New Class A Revolving Commitments, with $23.0 million remaining available to the Borrower under the Remaining Class B Revolving Commitments. The New Class A Revolving Commitments mature on June 30, 2025 and bear interest at either ABR plus 5.5% per annum or SOFR plus 6.5% per annum. The Remaining Class B Revolving Commitments continue to mature on September 13, 2024 and bear interest at either ABR plus 3.0% per annum or SOFR plus 4.0% per annum. In addition, Amendment No. 11 amended the Credit Agreement to, among other things, (i) increase the interest rate applicable to the Term Loan Facilities after August 31, 2024 to either ABR plus 7.0% or SOFR plus 8.0%, (ii)
GoHealth, Inc.2024 Form 10-Q  12


modify the financial covenant testing to be based on a Net Cash Leverage Ratio, as defined in Amendment No. 11, for reporting periods from December 31, 2023 and onwards, (iii) require the Borrower to repay $50.0 million and $25.0 million in borrowings under the Term Loan Facilities by April 12, 2024 and October 15, 2024, respectively together with applicable consent fees and (iv) modify the permitted usage of certain of the baskets available under the Credit Agreement. Finally, Amendment No. 11 provides that if the Borrower undertakes a securitization transaction prior to the maturity of the New Class A Revolving Commitments, the New Class A Revolving Commitments will further be reduced by 50.0%.
As of June 30,both March 31, 2024 and December 31, 2023, the CompanyBorrower had a principal amount of $110.4 million, $296.3 million and $96.1 million outstanding under the Incremental Term Loan Facility, the 2021 Incremental Term Loans, and the 2021-2 Incremental Term Loans, respectively. AsThe effective interest rate of December 31, 2022, the Company had a principal amount of $113.7 million, $305.4 million, and $99.0 million outstanding under the Incremental Term Loan Facility, the 2021 Incremental Term Loans,Facilities was 12.9% at March 31, 2024 and the 2021-2 Incremental Term Loans, respectively. The Term Loan Facilities’ effective interest rates were 12.8% at June 30, 2023 and 11.2%13.0% at December 31, 2022.2023.
The Term Loan Facilities are payable in quarterly installments in the principal amount of 0.25% of the original principal amount. The remaining unpaid balance on the Term Loan Facilities, together with all accrued and unpaid interest thereon, is due and payable on or prior to September 13, 2025.
Mandatory Prepayments
The Credit Agreement requires that the Borrower, following the end of each fiscal year, offer to repay the outstanding principal amount of all term loans under theRevolving Credit Facilities in an aggregate amount equal to (A) 50.0% of the excess cash flow of the Borrower and its restricted subsidiaries for such fiscal year if the Total Net Leverage Ratio (as defined in the Credit Agreement) is greater than 4.50:1.00, which percentage is reduced to 25% if the Total Net Leverage Ratio is less than or equal to 4.50:1.00 and greater than 4.00:1.00, which percentage is further reduced to 0% if the Total Net Leverage Ratio is less than or equal to 4.00:1.00, minus (B) at the option of the Borrower, (x) the aggregate amount of certain voluntary prepayments of term loans under

In addition, the Credit Agreement during such fiscal year or after year-end and prior to the time such Excess Cash Flow prepayment is due, (y) the aggregate principal amount of any voluntary prepayments of indebtedness under pari passu incremental facilities, incremental equivalent debt and/or certain refinancing indebtedness, made during such fiscal year or after such fiscal year and prior to the time such prepayment is due. With respect to each required offer of prepayment, each lender of the term loans has the right to refuse any such offer. To the extent any such offer of prepayment is refused, the aggregate amount of the offered prepayment shall be retained by the Borrower and its restricted subsidiaries. Subject to these terms, the lenders accepted the Company’s offer of prepayment in connection with fiscal year 2022, and as such, the Company paid $14.0 million during the second quarter of 2023. No other mandatory prepayments have been required or made during the three and six months ended June 30, 2023 and 2022.
Principal repayment obligations are reduced by the amount of any prepayment, and as such, the $14.0 million prepayment during the second quarter of 2023 satisfied the Company’s principal repayment obligations through the second quarter of 2025.
Revolving Credit Facilities
The Credit Agreement providedprovides for a $30.0 million aggregate principal amount senior secured revolving credit facility (thefacilities (collectively, the “Revolving Credit Facility”Facilities”). During 2020 and 2021, the Company entered into a series of amendmentsAs described above, prior to the Credit Agreement to provide for $28.0 million of incremental revolving credit (the “Incremental Revolving Credit Facilities”), and $142.0 million of incremental revolving credit (the “IncrementalAmendment No. 4 Revolving Credit Facility”), respectively, for a total amount of $200.0 million.
The Company collectively refers to11 the Revolving Credit Facility, the Incremental Revolving Credit Facilities and the Incremental No. 4 Revolving Credit Facility as the “Revolving Credit Facilities”. The Revolving Credit Facilities arewere separated into two classes of revolving commitments consisting of Class A Revolving Commitments in the amount of $30.0 million and Class B Revolving Commitments in the amount of $170.0 million.
million, each maturing on September 13, 2024. Effective March 12, 2024, Amendment No. 10, as described above, further provided that borrowings11 changed the two classes of revolving commitments resulting in a total of $88.5 million remaining available to the Borrower under the New Class A Revolving Commitments, and $23.0 million remaining available to the Borrower under the Remaining Class B Revolving Commitments. The New Class A Revolving Commitments mature on June 30, 2025 and bear interest at either ABR plus 5.50%5.5% per annum or SOFR plus 6.50%6.5% per annum. Borrowings under theThe Remaining Class B Revolving Commitments continue to mature on September 13, 2024 and bear interest at either ABR plus 3.00%3.0% per annum or SOFR plus 4.00%4.0% per annum. The Borrower is required to pay a commitment fee of 0.50%0.5% per annum under the Revolving Credit Facilities.
The CompanyBorrower had no amounts outstanding under the Class A Revolving Credit Facilities and Class B Revolving Credit Facilities as of both June 30, 2023March 31, 2024 and December 31, 2022.2023. The Revolving Credit Facilities have a remaining capacity of $111.5 million and $200.0 million in the aggregate as of June 30, 2023.March 31, 2024 and December 31, 2023, respectively.
OutstandingVoluntary Prepayment
The Borrower may voluntarily prepay outstanding borrowings under the RevolvingTerm Loan Facilities at any time in whole or in part without premium or penalty; provided, that, with respect to voluntary prepayments of the Term Loan Facilities and in certain other circumstances, the Borrower may have to pay a prepayment premium.
Mandatory Prepayments

As described above, Amendment No. 11 requires the Borrower to repay $50.0 million and $25.0 million in borrowings under the Term Loan Facilities by April 12, 2024 and October 15, 2024, respectively. The Borrower is also required to pay consent fees on April 12, 2024 and August 30, 2024 in the amount of 2.0% and 1.0%, respectively, of the aggregate principal balance of Term Loan Facilities outstanding after any mandatory prepayments. Subject to these terms, the Borrower paid $50.0 million and $9.1 million on April 4, 2024 related to the Term Loan Facilities repayment and the required consent fees, respectively.
The Credit Agreement requires the Borrower to repay amounts equal to 100.0% of the net cash proceeds of certain asset sales or other dispositions of property (including insurance and condemnation proceeds); provided, that, in the case of any prepayment events required in connection with certain dispositions and casualty events, if the net proceeds therefrom are invested (or committed to be invested) within twelve months after the receipt of such net proceeds, then no prepayment shall be required except to the extent such net proceeds have not been so invested (or committed to be invested) by the end of such 12-month period.
The Credit Agreement requires 100.0% of the net proceeds from the issuance or incurrence of certain indebtedness to be applied to prepay the term loans under the Term Loan Facilities, do not amortizeexcept to the extent the indebtedness constitutes refinancing indebtedness.
Guarantees and are due and payable on September 13, 2024.Security
The Borrower’s obligations under the Term Loan Facilities and Revolving Credit Facilities are guaranteed by Blizzard Midco, LLC and certain of the Borrower’s subsidiaries. All obligations under the Credit Agreement are secured by a first priority lien on substantially all of the assets of the Borrower, including a pledge of all of the equity interests of its subsidiaries.
Covenants and Other Matters

GoHealth, Inc.2024 Form 10-Q  13


The Credit Agreement contains customary eventsa number of defaultcovenants that, among other things and subject to certain exceptions, restrict the Borrower’s and its restricted subsidiaries’ ability to incur indebtedness; incur certain liens; consolidate, merge or sell or otherwise dispose of assets; make investments, loans, advances, guarantees and acquisitions; pay dividends or make other distributions on equity interests or redeem, repurchase or retire equity interests; enter into transactions with affiliates; alter the business conducted by the Borrower and subsidiaries; change their fiscal year; and amend or modify governing documents. In addition, the Credit Agreement contains financial and non-financial covenants.covenants including a financial covenant based on a Total Net Cash Leverage Ratio, which is defined as the ratio of consolidated total net debt as of the last day of the testing period to consolidated Cash EBITDA for the period. The CompanyTotal Net Cash Leverage Ratio must be below 4.50:1.00 for the period ending March 31, 2024 after which the Total Net Cash Leverage Ratio covenant will increase to 4.75:1.00 for the periods ending June 30, 2024 and September 30, 2024. For the period ending December 31, 2024 the Total Net Cash Leverage Ratio covenant will decrease to 3.50:1.00 before decreasing further to 2.75:1.00 on March 31, 2025 until the maturity of the Credit Agreement. The Borrower is in compliance with all covenants as of June 30, 2023.March 31, 2024.
The Credit Agreement also contains certain customary representations and warranties and affirmative covenants, and certain reporting obligations. In addition, the lenders under the Credit Facilities will be permitted to accelerate all outstanding borrowings and other obligations, terminate outstanding commitments and exercise other specified remedies upon the occurrence of certain events of default (subject to certain grace periods and exceptions), which include, among other things, payment defaults, breaches of representations and warranties, covenant defaults, certain cross-defaults and cross-accelerations to other indebtedness, certain events of bankruptcy and insolvency, certain judgments and changes of control. Subject to certain limited exceptions, substantially all of the Borrower’s assets are restricted from distribution.
5. STOCKHOLDERS' EQUITY
GoHealth, Inc.2023 Form 10-Q  14


In connection with the Company’s IPO in July 2020, the Company’s board of directors (the “Board of Directors”) approved an amended and restated certificate of incorporation and amended and restated bylaws. The amended and restated certificate of incorporation authorizes the issuance of up to 1,100,000,000 shares of Class A common stock, 690,000,000 shares of Class B common stock and 20,000,000 shares of preferred stock, each having a par value of $0.0001 per share. The number of shares of Class B common stock authorized is reduced for redemptions and forfeitures as they occur.
The Company’s amended and restated certificate of incorporation and the GHH, LLC Agreement require that the Company and GHH, LLC at all times to maintain a one-to-one ratio between the number of shares of Class A common stock issued by the Company and the number of LLC Interests owned by the Company, except as otherwise determined by the Company. Additionally, the Company’s amended and restated certificate of incorporation and the GoHealth Holdings,GHH, LLC Agreement require that the Company and GHH, LLC at all times maintain a one-to-one ratio between the number of shares of Class B common stock owned by the Continuing Equity Owners and their respective permitted transferees and the number of LLC Interests owned by the Continuing Equity Owners and their respective permitted transferees, except as otherwise determined by the Company. Only the Continuing Equity Owners and the permitted transferees of Class B common stock are permitted to hold shares of Class B common stock. Shares of Class B common stock are transferable for shares of Class A common stock only together with an equal number of LLC Interests.
Holders of shares of the Company’s Class A common stock are entitled to one vote for each share held of record on all matters submitted to a vote of stockholders. Each share of Class B common stock entitles its holders to one vote per share on all matters presented to the Company’s stockholders generally. Holders of shares of Class B common stock will vote together with holders of the Company’s Class A common stock as a single class on all matters presented to the Company’s stockholders for their vote or approval, except for certain amendments to the Company’s amended and restated certificate of incorporation or as otherwise required by applicable law or the amended and restated certificate of incorporation. Holders of ourthe Class B common stock are not entitled to participate in any dividends declared by ourthe Board of Directors. Under the terms of the Company’s amended and restated certificate of incorporation, the Company’s Board of Directors is authorized to direct the Company to issue shares of preferred stock in one or more series without stockholder approval. The Company’s Board of Directors has the discretion to determine the rights, preferences, privileges and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges and liquidation preferences, of each series of preferred stock.
The Continuing Equity Owners may, subject to certain exceptions, from time to time at each of their options require GHH, LLC to redeem all or a portion of their LLC Interests in exchange for, at the Company’s election (determined by at least two of the Company’s independent directors who are disinterested), newly-issued shares of Class A common stock on a one-for-one basis, or to the extent there is cash available from a secondary offering, a cash payment equal to a volume weighted average market price of one share of the Company’s Class A common stock for each LLC Interest so redeemed, in each case, in accordance with the terms of the GoHealth Holdings,GHH, LLC Agreement.
The weighted average ownership percentages for the applicable reporting periods are used to attribute net income (loss) and other comprehensive income (loss) to the Company and the non-controlling interest holders. Non-controlling interest represents the economic interest in GHH, LLC held directly or indirectly by the Continuing Equity Owners. The non-controlling interest holders' weighted average ownership percentages for the three and six months ended June 30,March 31, 2024 and 2023 were 58.8%56.8% and 59.0%59.3%, respectively. The non-controlling interest holders' weighted average ownership percentages for the three and six months ended June 30, 2022 were 61.5% and 62.6%, respectively.
GoHealth, Inc.2024 Form 10-Q  14


Upon the Company’s dissolution or liquidation, after payment in full of all amounts required to be paid to creditors and to the holders of preferred stock having liquidation preferences, if any, holders of Class A common stock and Class B common stock will be entitled to receive ratable portions of the Company’s remaining assets available for distribution; provided, that the holders of Class B common stock shall not be entitled to receive more than $0.0001 per share of Class B common stock and upon receiving such amount, shall not be entitled to receive any of the Company’s other assets or funds with respect to such shares of Class B common stock.
Redeemable Convertible Preferred Stock
On September 23, 2022 (the “Closing Date”), the Company issued 50,000 shares of the Company’s Series A Convertible Perpetual Preferred Stock (the “Issuance”), par value $0.0001 per share (the “Series A redeemable convertible preferred stock”), to Anthem Insurance Companies, Inc. and GH 22 Holdings, Inc. (the “Purchasers”) for an aggregate purchase price of $50.0 million, at $1,000 per share of the Series A redeemable convertible preferred stock.
The Company is authorized to issue 20,000,000 shares of preferred stock with a par value of $0.0001 per share as of both June 30, 2023March 31, 2024 and December 31, 2022,2023, which had not been designated to any specific classes of preferred stock prior to the Closing Date. On the Closing Date, the Company designated and authorized the issuance of 50,000 shares under the Series A redeemable convertible preferred stock and 200,000 shares under the Series A-1 Convertible Non-Voting Perpetual Preferred Stock (the “Series A-1 convertible preferred stock”).
The Series A redeemable convertible preferred stock ranks senior to the shares of the Company’s Class A common stock and Class B common stock with respect to dividend rights and rights on the distribution of assets on any voluntary or involuntary
GoHealth, Inc.2023 Form 10-Q  15


liquidation, dissolution or winding up of the affairs of the Company. The Series A redeemable convertible preferred stock has an initial liquidation preference of $1,000 per share, which shall increase by accumulated quarterly dividends that are not paid in cash (“compounded dividends”). Dividends on each share of Series A redeemable convertible preferred stock shall accrue at an annual rate equal to 7%. Holders of Series A-1 convertible preferred stock are only entitled to dividends if the Company declares such dividends. For the three and six months ended June 30, 2023,March 31, 2024, the Company paidaccrued $0.9 million and $1.8 million, respectively, of dividends relating to the Series A-1A redeemable convertible preferred stock that were not paid in cash. The accrued dividends are included in temporary equity on the Condensed Consolidated Balance Sheets. For the three months ended March 31, 2023, the Company paid in cash $0.9 million of dividends relating to the Series A redeemable convertible preferred stock.
The Series A redeemable convertible preferred stock is convertible in full at the option of the holders into the number of shares of Class A common stock equal to the quotient of (a) the sum of (x)(i) the liquidation preference (reflecting increases for compounded dividends) plus (y)(ii) the accrued dividends with respect to each share of convertible preferred stock as of the applicable conversion date divided by (b) the conversion price ($9.60 as of June 30, 2023March 31, 2024 and subject to adjustment based on certain changes to the Company’s Class A common stock) as of the applicable conversion date. Notwithstanding the foregoing, a holder of Series A redeemable convertible preferred stock may elect to receive upon conversion, in lieu of the shares of Class A common stock otherwise deliverable, one share of Series A-1 convertible preferred stock for every 1,000 shares of Class A common stock otherwise deliverable upon conversion. The Series A-1 convertible preferred stock will be essentially a substitute for the Class A common stock in the form of non-voting preferred stock.
The terms of the Series A redeemable convertible preferred stock and Series A-1 convertible preferred stock contain certain anti-dilution adjustments. Subject to certain conditions, at any time after the third anniversary of the Closing Date, if the volume weighted average price per share of Class A common stock on Nasdaq is equal to or greater than 150%150.0% of the then-applicable conversion price for each of at least twenty (20) trading days, whether or not consecutive, in any period of thirty (30) consecutive trading days ending on and including the trading day immediately before the Company provides the holders with notice of its election to convert all or a portion of the Series A redeemable convertible preferred stock into the relevant number of shares of Class A common stock or Series A-1 convertible preferred stock (at the election of the holder), the Company may elect to convert all or a portion of the Series A redeemable convertible preferred stock into the relevant number of shares of Class A common stock or Series A-1 convertible preferred stock.
In the event of any voluntary or involuntary liquidation, dissolution or winding up of the affairs of the Company, the holders of shares of Series A-1 convertible preferred stock (if issued upon conversion of the Series A redeemable convertible preferred stock) will be entitled, out of assets legally available therefor, and subject to the rights of the holders of any senior stock (including the Series A redeemable convertible preferred stock) or parity stock (including the Class A and Class B common stock) and the rights of the Company’s existing and future creditors, to receive an aggregate amount per share equal to 1,000 (as may be adjusted) times the aggregate amount to be distributed per share to holders of shares of Class A common stock. Each holder of a whole share of Series A-1 convertible preferred stock (if issued upon conversion of the Series A redeemable convertible preferred stock) shall be entitled to receive when, as and if declared by the Company’s boardBoard of directorsDirectors out of funds legally available for the purpose, an amount per share equal to 1,000 (as may be adjusted) times the aggregate per share amount of all cash dividends, and 1,000 (as may be adjusted) times the aggregate per share amount (payable in kind) of all non-cash dividends or other distributions other than a dividend payable in shares of Class A common stock or a subdivision of the outstanding shares of Class A common stock (by reclassification or otherwise), declared on each share of Class A common stock since the first issuance of any share of Series A-1 convertible preferred stock. Each holder of Series A-1 convertible preferred
GoHealth, Inc.2024 Form 10-Q  15


stock (if issued upon conversion of the Series A redeemable convertible preferred stock) will have the right, at such holder’s option, to convert in full each share of such holder’s Series A-1 convertible preferred stock at such time into the number of shares of Class A common stock based upon a conversion ratio of 1,000 shares of Class A common stock for each share of Series A-1 convertible preferred stock (such ratio being subject to adjustment).
Under the Certificate of Designations, holders of the Series A redeemable convertible preferred stock are entitled to vote with the holders of the Class A common stock on an as-converted basis on all matters submitted to a vote of the holders of the Class A common stock. Notwithstanding the foregoing: (1) the lead Purchaser’s voting rights shall not exceed 9.99% of the voting rights associated with the issued and outstanding shares of capital stock of the Company at any time; and (2) the voting rights of the Purchasers holding Series A redeemable convertible preferred stock, voting on an as-converted basis with the holders of the Class A common stock and the holders of any other class or series of capital stock of the Company then entitled to vote, shall be capped at the maximum amount that would not result in requiring shareholder approval for the exercise of such voting rights pursuant to the rules of Nasdaq.Nasdaq Rules. The Series A-1 convertible preferred stock is not entitled to vote with the Class A common stock on matters submitted to a vote of the holders of the Class A common stock and will have no voting rights except as required by applicable law.
In addition, holders of the Preferred Stockpreferred stock are entitled to a separate class vote with respect to, among other things, amendments to the Company’s organizational documents that materially, adversely and disproportionately affect the Series A redeemable convertible preferred stock, authorizations or issuances by the Company of securities that are senior to or pari passu with the Series A redeemable convertible preferred stock and issuing any debt security (for the avoidance of doubt, excluding any draws under the Company’s Existing Credit Agreement referenced in the Certificate of Designations), if the Company’s Consolidated Total Net Debt (as defined in the Certificate of Designations) following such action would exceed four times the Company’s Consolidated EBITDA (as defined in the Certificate of Designations) for the Company’s most recently completed four consecutive fiscal quarters.
GoHealth, Inc.2023 Form 10-Q  16


At any time following the fifth anniversary of the Closing Date, the Company may redeem the Series A redeemable convertible preferred stock, in whole or in part, for a per share amount in cash equal to the liquidation preference (reflecting increases for compounded dividends) thereof plus all accrued dividends as of the applicable redemption date. Upon certain change of control events involving the Company, (i) a holder of the Series A redeemable convertible preferred stock may, so long as such payment would not otherwise result in a breach of, or event of default under, then-existing credit agreements, indentures or other financing arrangements, require the Company to purchase and (ii) subject to a holder’s right to convert its shares of Series A redeemable convertible preferred stock into Class A common stock or Series A-1 convertible preferred stock at the then-current conversion price, the Company may elect to purchase, all or a portion of such holder’s shares of Series A redeemable convertible preferred stock that have not been so converted, in each case at a purchase price per share of Series A redeemable convertible preferred stock, payable in cash, equal to (A)(i) if the change of control effective date occurs at any time prior to the fifth anniversary of the Closing Date, 160%160.0% of a purchaser’sPurchaser’s original investment amount and (B)(ii) if the change of control effective date occurs on or after the fifth anniversary of the Closing Date, the liquidation preference (reflecting increases for compounded dividends) of such share of Series A redeemable convertible preferred stock plus the accrued dividends in respect of such share of Series A redeemable convertible preferred stock as of the change of control purchase date.
The Purchasers have entered into a customary registration rights agreement with respect to shares of Class A common stock held by the Purchasers issued upon any future conversion of the Series A redeemable convertible preferred stock or Series A-1 convertible preferred stock.
In connection with the Issuance, the Company, as the managing member of GHH, LLC, caused the GHH, LLC (i) to issue to the Company, in exchange for the proceeds from the Issuance, Series A preferred units (the “Preferred Units”) and (ii) to authorize another series of preferred units, (the “Series A-1 Preferred Units”), in each case having an aggregate liquidation preference and having terms substantially economically equivalent to the aggregate liquidation preference and the economic terms of the Series A redeemable convertible preferred stock and the Series A-1 convertible preferred stock, respectively, and entered into Amendment No. 2 to the GoHealth Holdings,GHH, LLC Agreement (“Amendment No. 2”) to effectuate the same.

The Company classifies the Series A redeemable convertible preferred stock and Series A-1 convertible preferred stock outside of permanent equity as temporary equity since the redemption of such shares is not solely within the Company’s control. The Company does not remeasure the redeemable convertible preferred stock because it is not currently redeemable and not probable of becoming redeemable. The redeemable convertible preferred stock was recorded at fair value upon issuance, net of issuance costs of $1.6 million.

Reverse Stock Split

On November 10, 2022, the Board of Directors approved a resolution to effect a reverse stock split such that every holder of Class A common stock and Class B common stock (together, “Common Stock”) received one share of the respective class of stock for every fifteen shares of Common Stock held (the “Reverse Stock Split”). The Reverse Stock Split also adjusted the LLC Interests. The authorized shares and par value per share of the Common Stock and preferred stock were not adjusted as a result of the Reverse Stock Split. With respect to the Series A redeemable convertible preferred stock, the conversion price was automatically adjusted to account for the Reverse Stock Split for such shares. Share and per share amounts of preferred stock were not adjusted as a result of the Reverse Stock Split. The Reverse Stock Split became effective on November 17, 2022.
6. SHARE-BASED COMPENSATION PLANS
The following table summarizes share-based compensation expense by operating function for the periods presented:
Three months ended Jun. 30,Six months ended Jun. 30,
(in thousands)2023202220232022
Marketing and advertising$164 $215 $230 $656 
Customer care and enrollment725 624 1,329 1,255 
Technology921 627 1,688 1,609 
General and administrative8,310 12,791 13,457 15,892 
Total share-based compensation expense$10,120 $14,257 $16,704 $19,412 
Stock Appreciation Rights
On June 6, 2022, the Founders were each granted two stock appreciation rights ("SARs") under the 2020 Employment Inducement Award Plan. The first SAR commenced on June 6, 2022, and the second SAR commenced on June 21, 2023. Each SAR will be settled in cash with an aggregate commencement date value equal to $1.5 million (the number of shares to be determined by dividing such value by the per share Black-Scholes valuation as of the date of commencement), will have an exercise price equal to the fair market value of a share of the Company’s common stock on the date of commencement and will vest in full on the three-year anniversary of the date of commencement. For the SARs with no future service requirement, the total initial fair value of the awards was recorded as an expense at the time of the grant. The fair value of the awards with a future service requirement was recognized on a straight-line basis over the requisite service period (which service period has now been
GoHealth, Inc.20232024 Form 10-Q  1716


completed). The fair value of
Three months ended Mar. 31,
(in thousands)20242023
Marketing and advertising$76 $66 
Consumer care and enrollment324 604 
Technology239 767 
General and administrative(1)
1,144 5,147 
Total share-based compensation expense$1,783 $6,584 
(1) For the SARs is revalued (mark-to-market) each reporting period using the Black-Scholes valuation model based on the Company’s period-end stock price. SARs are liability-classified awards,three months ended March 31, 2024 and as such, are recorded as a liability on the Condensed Consolidated Balance Sheet. The Company had a2023, share-based compensation liabilityexpense includes expense related to the SARs of $8.6 million and $5.0 million as of June 30, 2023 and December 31, 2022, respectively.
Performance Stock Unitsstock appreciation rights (“PSUs”)

During 2021, the Company granted to certain of its employees 32,579 shares of Class A common stock issuable pursuant to performance stock units (“PSUs”). The criteria for the market-based PSUs is based on the Company’s total shareholder return (“TSR”) relative to the TSR of the common stock of a predefined industry peer group. TSR is measured at the end of the performance period, which is generally the period commencing on the grant date and ending on the three-year anniversary of the grant date. Depending on the relative TSR achieved, the number of PSUs earned can vary from 0% of the target award to a maximum of 200% of the target award. The Company estimated the grant-date fair value of the awards subject to a market condition using a Monte Carlo simulation model, using the following weighted-average assumptions: risk-free interest rate of 0.2% and annualized volatility of 72.0%. The grant date fair value of the PSUs was $332.55 per share. The Company recognizes the grant date fair value of PSUs as compensation expense on a straight-line basis over the three-year performance period.
On June 7, 2022, the Company granted, to certain of its executives, an aggregate of 194,444 shares of Class A common stock issuable pursuant to volume weighted average PSUs (“VWAPs”). The number of shares issued on the three-year anniversary of the date of grant is based on volume weighted average price performance over such three year period (“Three Year VWAP”) in the following percentages: (i) 50% if the Three Year VWAP is equal to or greater than $30.00 but less than $45.00; (ii) 100% if the Three Year VWAP is equal to or greater than $45.00 but less than $60.00; (iii) 150% if the Three Year VWAP is equal to or greater than $60.00 but less than $90.00; and (iv) 200% if the Three Year VWAP is equal to or greater than $90.00. The Company estimated the grant-date fair value of the awards subject to a market condition using a Monte Carlo simulation model, using the following weighted-average assumptions: risk-free interest rate of 2.9% and annualized volatility of 94%. The grant-date fair value of the VWAPs was $8.25 per share. The Company recognizes the grant-date fair value of VWAPs as compensation expense on a straight-line basis over the three-year performance period.
On April 10, 2023, the Company granted, to certain of its executives, an aggregate of 100,000 shares of Class A common stock issuable pursuant to PSUs. The criteria for the performance-based PSUs are based on the Company’s compound annual growth rate in Adjusted EBITDA (“Adjusted EBITDA CAGR Percentage”SARs”), determined based on the Company’s Adjusted EBITDA for calendar year 2025 compared to the Company’s reported 2022 Adjusted EBITDA. Depending on the Adjusted EBITDA CAGR Percentage achieved, the number of PSUs earned can vary from 0% of the target award to a maximum of 200% of the target award and will vest on the date the Company files its Annual Report on Form 10-K for the fiscal year ending December 31, 2025, subject to the participants’ continued service with the Company through that date. The grant-date fair value of the PSUs was $14.10 per share, which was the Company’s closing stock price on the grant date. The Company will accrue compensation cost on a straight-line basis over the requisite service period for the PSUs that are expected to vest. The Company will reassess the probability of achieving the performance condition at each reporting period and record a cumulative catch-up adjustment for any changes to its assessment, which could be either a reversal or increase in expense.
For the three and six months ended June 30, 2023, the Company recorded share-based compensation expense related to PSUs of $0.8 million and $1.5 million, respectively. For the three and six months ended June 30, 2022, the Company recorded share-based compensation expense related to PSUs of $0.2 million and $1.0 million, respectively.liability classified awards.
7. NET LOSS PER SHARE
Basic loss per share is computed by dividing net loss attributable to common stockholders by the weighted-average number of shares of Class A common stock outstanding during the period. Diluted loss per share is computed giving effect to all potentially dilutive shares. Diluted loss per share for all periods presented is the same as basic loss per share as the inclusion of potentially issuable shares would be antidilutive.
A reconciliation of the numerator and denominator used in the calculation of basic and diluted net loss per share of Class A common stock is as follows:
GoHealth, Inc.2023 Form 10-Q  18


Three months ended Jun. 30,Six months ended Jun. 30,
Three months ended Mar. 31,
Three months ended Mar. 31,
Three months ended Mar. 31,
(in thousands, except per share amounts)
(in thousands, except per share amounts)
(in thousands, except per share amounts)(in thousands, except per share amounts)2023202220232022
Numerator:Numerator:
Numerator:
Numerator:
Net lossNet loss$(70,229)$(113,752)$(92,772)$(150,993)
Net loss
Net loss
Less: Net loss attributable to non-controlling interests
Less: Net loss attributable to non-controlling interests
Less: Net loss attributable to non-controlling interestsLess: Net loss attributable to non-controlling interests(41,287)(69,933)(54,651)(93,691)
Net loss attributable to GoHealth, Inc.Net loss attributable to GoHealth, Inc.(28,942)(43,819)(38,121)(57,302)
Net loss attributable to GoHealth, Inc.
Net loss attributable to GoHealth, Inc.
Less: Dividends accumulated on redeemable convertible preferred stock
Less: Dividends accumulated on redeemable convertible preferred stock
Less: Dividends accumulated on redeemable convertible preferred stockLess: Dividends accumulated on redeemable convertible preferred stock891 — 1,783 — 
Net loss attributable to common stockholdersNet loss attributable to common stockholders(29,833)(43,819)(39,904)(57,302)
Net loss attributable to common stockholders
Net loss attributable to common stockholders
Denominator:Denominator:
Weighted-average shares of Class A common stock outstanding—basic9,122 8,296 9,044 8,023 
Effect of dilutive securities— — — — 
Weighted-average shares of Class A common stock outstanding—diluted9,122 8,296 9,044 8,023 
Denominator:
Denominator:
Weighted-average shares of Class A common stock outstanding—basic and diluted
Weighted-average shares of Class A common stock outstanding—basic and diluted
Weighted-average shares of Class A common stock outstanding—basic and diluted
Net loss per share of Class A common stock—basic and dilutedNet loss per share of Class A common stock—basic and diluted$(3.27)$(5.28)$(4.41)$(7.14)
Net loss per share of Class A common stock—basic and diluted
Net loss per share of Class A common stock—basic and diluted
The following number of shares were excluded from the calculation of diluted loss per share because the effect of including such potentially dilutive shares would have been antidilutive:
Jun. 30,
Mar. 31,
Mar. 31,
Mar. 31,
(in thousands)
(in thousands)
(in thousands)(in thousands)20232022
Class A common stock issuable pursuant to equity awardsClass A common stock issuable pursuant to equity awards2,460 1,387 
Class A common stock issuable pursuant to equity awards
Class A common stock issuable pursuant to equity awards
Class A common stock issuable pursuant to conversion of redeemable convertible preferred stock
Class A common stock issuable pursuant to conversion of redeemable convertible preferred stock
Class A common stock issuable pursuant to conversion of redeemable convertible preferred stockClass A common stock issuable pursuant to conversion of redeemable convertible preferred stock3,873 — 
Class B common stockClass B common stock12,818 13,170 
Class B common stock
Class B common stock
Shares of Class B common stock do not share in earnings and are not participating securities. Accordingly, separate presentation of loss per share of Class B common stock under the two-class method has not been presented. Shares of Series A redeemable convertible preferred stock are not participating securities as holders receive a contractual dividend. Accordingly, separate presentation of loss per share of Series A redeemable convertible preferred stock under the two-class method has not been presented.
8. INCOME TAXES
The Company is taxed as a corporation for income tax purposes and is subject to federal, state and local taxes on the income allocated to it from GHH, LLC based upon the Company’s economic interest in GHH, LLC. The Company is the sole managing member of GHH, LLC and, as a result, consolidates the financial results of GHH, LLC. GHH, LLC is a limited liability company taxed as a partnership for income tax purposes, and the subsidiaries of GHH, LLC are limited liability companies for income tax purposes except for a subsidiary and its foreign subsidiary, which are taxedis treated as a corporation and foreign disregarded entity, respectively.entity. As such,a partnership, GHH, LLC does not pay any federal income taxes, as income or loss is included in the tax returns of the individual members. Additionally,Prior to April 1, 2023, certain of the Company’s wholly-owned entities were taxed as corporations areand subject to federal state, and foreignstate income taxes in the jurisdictions in which they operate, andoperated. Additionally, the Company’s foreign subsidiary is subject to foreign income taxes in the jurisdiction in which it operates. The accruals for such taxes are included in the Condensed Consolidated Financial Statements.
GoHealth, Inc.2024 Form 10-Q  17


The Company’s effective tax rate for the three and six months ended June 30,March 31, 2024 and 2023 was 0.10%0.33% and 0.13%, respectively. The Company’s effective tax rate for the three and six months ended June 30, 2022 was 0.00% and (0.31)%0.19%, respectively. The effective tax rate for each period is lower than the statutory tax rate primarily due to the effect of loss entities for which the Company excludes from its effective tax rate calculation and loss attributable to non-controlling interests.
Tax Receivable Agreement
In connection with the IPO, the Company entered into a Tax Receivable Agreement with GHH, LLC, the Continuing Equity Owners and the Blocker Shareholders that will provide for the payment by the Company to the Continuing Equity Owners and the Blocker Shareholders of 85% of the amount of tax benefits, if any, that the Company actually realizes (or in some circumstances is deemed to realize). The amounts payable under the Tax Receivable Agreement will vary depending upon a number of factors, including the amount, character and timing of the taxable income of the Company in the future. As of both March 31, 2024 and December 31, 2022 and June 30, 2023 the liability related to the Tax Receivable Agreement was $0.6$0.8 million. Should the Company determine that changes to amounts currently recorded arising from theany additional Tax Receivable Agreement areliability is considered probable at a future date based on new information, such additional amountsany changes will be recorded within income from continuing operationsearnings at that time.
9. REVENUE
GoHealth, Inc.2023 Form 10-Q  19


Revenue Recognition for Variable Consideration
The Company’s variable consideration includes the total estimated lifetime value (“LTV”) it expects to receive for selling an insurance product afterexpected amount of initial commissions received from the health plan partner approves an application.partners and any renewal commissions to be paid on such placement as long as the policyholder remains with the same insurance product, also known as the total estimated LTV of the policy. The consideration is variable based on the estimated amount of time it estimates a policy will remain in force, which is based on historical experience or health plan partner experience to the extent available, industry data, and expectations as to future retention rates. Additionally, the Company considers the application of a constraint and only recognizes the amount of variable consideration that it believes is probable that it will be entitled to receive and will not be subject to a significant revenue reversal in the future.
On a quarterly basis, the Company re-estimates LTV at a vintage level for outstanding vintages, which takes into account cash received as compared to the original estimates and reviews and monitors changes in the data used to estimate LTV. Changes in LTV may result in an increase or a decrease to revenue and a corresponding change to commissions receivable. The Company analyzes these differences and to the extent the Company believes differences in the estimates are indicative of a change to prior period LTVs, the Company will adjust revenue for the affected vintages at the time such determination is made and when it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur. For the three and six months ended June 30,March 31, 2024 and 2023, the Company recorded no revenue adjustments. For the three and six months ended June 30, 2022, the Company recorded negative revenue adjustments of $3.6 million and $6.2 million, respectively, for changes in estimates relating to performance obligations satisfied in prior periods.
Disaggregation of Revenue
The table below depicts the disaggregation of revenue and is consistent with how the Company evaluates its financial performance:
Three months ended Jun. 30,Six months ended Jun. 30,
Three months ended Mar. 31,
Three months ended Mar. 31,
Three months ended Mar. 31,
(in thousands)
(in thousands)
(in thousands)(in thousands)2023202220232022
Medicare RevenueMedicare Revenue
Medicare Revenue
Medicare Revenue
Agency RevenueAgency Revenue
Commission Revenue1
$87,403 $109,027 $184,934 $300,720 
Agency Revenue
Agency Revenue
Commission Revenue(1)
Commission Revenue(1)
Commission Revenue(1)
Partner Marketing and Other Revenue
Partner Marketing and Other Revenue
Partner Marketing and Other RevenuePartner Marketing and Other Revenue23,195 21,379 50,319 55,406 
Total Agency RevenueTotal Agency Revenue110,598 130,406 235,253 356,126 
Total Agency Revenue
Total Agency Revenue
Non-Agency Revenue
Non-Agency Revenue
Non-Agency RevenueNon-Agency Revenue28,104 3,548 73,076 9,300 
Total Medicare RevenueTotal Medicare Revenue138,702 133,954 308,329 365,426 
Total Medicare Revenue
Total Medicare Revenue
Other Revenue
Other Revenue
Other RevenueOther Revenue
Non-Encompass BPO Services RevenueNon-Encompass BPO Services Revenue2,528 23,119 9,322 58,056 
Non-Encompass BPO Services Revenue
Non-Encompass BPO Services Revenue
Other Revenue
Other Revenue
Other RevenueOther Revenue1,549 1,581 8,286 5,765 
Total Other RevenueTotal Other Revenue4,077 24,700 17,608 63,821 
Total Net Revenue$142,779 $158,654 $325,937 $429,247 
Total Other Revenue
Total Other Revenue
Total Net Revenues
Total Net Revenues
Total Net Revenues

(1)CommissionsCommission revenue excludes commissions generated through the Company’s non-EncompassNon-Encompass BPO Services as well as from the sale of individual and family plan insurance products.

Medicare RevenueRevenue:: The primary services provided by the Company relate to the sale and administration of Medicare insurance products through either the agency model or the non-agency model. The agency model refers to the commission revenue and partner marketing revenue the Company receives when GoHealth agents or the Company’s independent network of outsourced agents enroll the consumer and submit the policy application to the health plan partner, becoming the agent of record. The Company recognizes commission revenue from the sale of insurance products at the point when health plan partners approve an
GoHealth, Inc.2024 Form 10-Q  18


insurance application produced by the Company. The Company records as commission revenue the expected amount of initial commissions received from the health plan partners and any renewal commissions to be paid on such placement as long as the policyholder remains with the same insurance product, which represents the LTV it expects to receive for selling the product after the health plan partner approves an application. As part of its estimation process, the Company constrains revenue such that the amount of revenue recognized is the amount the Company believes is probable will not result in a significant reversal in the future. The Company records partner marketing services over time based on delivering call volumes or providing marketing services.

Non-agency revenue refers to services provided by the Company that support enrollment and engagement activities in which the Company is not the agent of record. The non-agency model moves away from the agency structure in that cash is collected in advance or in close proximity to the point in time revenue is recognized. Non-agency revenue includes enrollment and engagement services through Encompass Connect and Encompass Engage. Encompass Connect is designed to provide enrollment related services to our participating partners. The Company is compensated for generating and transferring leads to the health plan partners, at which time the health plan partner representative will enroll and submit the application, becoming the agent of record. Revenue is recognized at the point in time the lead is transferred. Encompass Engage includes post-enrollment member outreach and engagement services, including facilitating an onboarding experiencesexperience customized to members’a member’s plan and health needs. The Company recognizes Encompass Engage revenue overat the point in time that the service is provided based on member retention and providing post-enrollment services.
GoHealth, Inc.2023 Form 10-Q  20



Other RevenueRevenue:: Other revenue is comprised of Non-Encompass BPO Services, which refers to programs in which GoHealth-employed agents are dedicated to certain health plans and agencies we partner with outside of the Encompass model. These services include commissionscommission revenue and partner marketing revenue that is directly attributable to non-EncompassNon-Encompass BPO Services. The remaining revenue relates primarily to revenue generated from the sale of individual and family plan insurance products and ancillary services.
Contract Assets and Liabilities
The Company records contract assets and contract liabilities from contracts with customers as it relates to commissions receivable, commissions payable and deferred revenue. Commissions receivable represents estimated variable consideration for commissions to be received from health plan partners for performance obligations that have been satisfied. Commissions payable represents estimated commissions to be paid to the Company’s external agents and other partners.
The Company had unbilled receivables for performance-based enrollment fees and non-agency revenue as of March 31, 2024 and December 31, 2023 of $8.8 million and $36.0 million, respectively, which are recorded in prepaid expenses and other current assets on the Condensed Consolidated Balance Sheets. In addition, the Company had accrued payments for revenue share as of March 31, 2024 and December 31, 2023 of $12.7 million and $14.8 million, respectively, which are recorded in accrued liabilities. There are no other contract assets or contract liabilities recorded by the Company.
Deferred revenue includes amounts collected for partner marketing services and non-agency revenue and technology licensing and implementation fees in advance of the Company satisfying its performance obligations for such customers. The decrease in deferred revenue during the sixthree months ended June 30,March 31, 2024 compared to December 31, 2023 was primarily due to less cash received in the current quarteras of March 31, 2024 compared to December 31, 2023 for marketing, administrative and prospect qualificationenrollment fees in advance of performing partner marketing and enrollmentsuch services that we expectthe Company expects to satisfy within the next twelve months.
The During the three months ended March 31, 2024 and 2023, the Company had unbilled receivables for performance-based enrollment fees and non-agencyrecognized revenue as of June 30, 2023 and December 31, 2022 of $0.8 million and $39.6 million, respectively, which arethat was recorded in prepaid expenses and other current assetsdeferred revenue on the Condensed Consolidated Balance Sheets. There are no other contract assets or contract liabilities recorded bySheets at the Company.
Forbeginning of the three and six months ended June 30, 2023, the Company recognized $4.8respective fiscal year of $34.9 million and $45.3$40.5 million, respectively, of revenue that was deferred as of December 31, 2022. For both the three and six months ended June 30, 2022, the Company recognized $0.1 million of revenue that was deferred as of December 31, 2021.respectively.
Commissions Receivable
Commissions receivable activity is summarized as follows:
Six months ended Jun. 30,
Three months ended Mar. 31,Three months ended Mar. 31,
(in thousands)(in thousands)20232022(in thousands)20242023
Beginning balanceBeginning balance$1,031,433 $1,262,507 
Commission revenue188,157 327,677 
Commission revenue(1)
Cash receiptsCash receipts(308,061)(429,605)
Allowance for credit lossAllowance for credit loss33 67 
Ending balanceEnding balance$911,562 $1,160,646 
Less: Commissions receivable - currentLess: Commissions receivable - current294,319 198,647 
Commissions receivable - non-currentCommissions receivable - non-current$617,243 $961,999 

(1)Commission revenue excludes commissions generated through the Company’s Non-Encompass BPO Services as well as from the sale of individual and family plan insurance products.
GoHealth, Inc.2024 Form 10-Q  19


The Company’s contracts with health plan partners expose it to credit risk because a financial loss could be incurred if the counterparty does not fulfill its financial obligation. While the Company is exposed to credit losses due to the potential non-performance of its counterparties, the Company considers thethis risk of thisto be remote. The Company estimates the allowance for credit losses using available information from internal and external sources related to historical experiences, current conditions and forecasts. Estimates of loss given default are determined by using historical collections data as well as historical information obtained through research and review of other peer companies. The estimated exposure of default is determined by applying these internal and external factors to the commission receivable balances. The Company estimates the maximum credit risk in determining the commissions receivable amount recorded on the balance sheet.Condensed Consolidated Balance Sheets.
Significant Customers
The following table presents health plan partners representing 10% or more of the Company’s total revenue for the periods indicated:
GoHealth, Inc.2023 Form 10-Q  21


Three months ended Jun. 30,Six months ended Jun. 30,
2023202220232022
Three months ended Mar. 31,
Three months ended Mar. 31,
Three months ended Mar. 31,
2024
2024
2024
Aetna
Aetna
Aetna
Elevance Health
Elevance Health
Elevance Health
Humana
Humana
HumanaHumana41 %29 %39 %26 %
UnitedUnited20 %17 %20 %18 %
Elevance Health17 %23 %18 %24 %
Centene%14 %%15 %
United
United
Concentration of Credit Risk
The Company does not require collateral or other security in granting credit. As of June 30, 2023, two customers each represented 10% or more of the Company’s total accounts receivable and unbilled receivables and, in aggregate, represented 91%, or $33.5 million, of the combined total. As of DecemberMarch 31, 2022,2024, three customers each represented 10% or more of the Company’s total accounts receivable and unbilled receivables and, in aggregate, represented 85%93.3%, or $37.6$16.8 million, of the combined total. As of December 31, 2023, three customers each represented 10% or more of the Company’s total accounts receivable and unbilled receivables and, in aggregate, represented 88.3%, or $32.1 million, of the combined total. Unbilled receivables are included in prepaid expense and other current assets on the Condensed Consolidated Balance Sheets.
10. LEASES
The Company has entered into operating agreements with lease periods expiring between 20232024 and 2032. Lease expense for operating lease payments is recognized on a straight-line basis over the lease term.
The Company entered into a lease agreement for a site in Chicago at the Merchandise Mart for our corporate headquarters. The lease commenced on July 5, 2023 with a lease term through June 30, 2028.
Components of lease expense are as follows, all recorded within operating expenses in the Condensed Consolidated Statement of Operations:
Three months ended Mar. 31,
Three months ended Mar. 31,
Three months ended Mar. 31,
(in thousands)
(in thousands)
(in thousands)
Three months ended Jun. 30,Six months ended Jun. 30,
(in thousands)2023202220232022
Finance lease cost1
$— $41 $— $102 
Operating lease costOperating lease cost1,956 2,055 4,048 4,002 
Short-term lease cost2
14 170 33 253 
Variable lease cost3
131 93 254 137 
Operating lease cost
Operating lease cost
Short-term lease cost(1)
Short-term lease cost(1)
Short-term lease cost(1)
Variable lease cost(2)
Variable lease cost(2)
Variable lease cost(2)
Sublease income
Sublease income
Sublease incomeSublease income(396)(274)(784)(549)
Total net lease expenseTotal net lease expense$1,705 $2,085 $3,551 $3,945 
Total net lease expense
Total net lease expense

(1)Primarily consists of amortization of finance lease right-of-use assets and an immaterial amount of interest on finance lease liabilities recorded in operating expenses and interest expense in the Condensed Consolidated Statements of Operations.
(2)Includes costs related to leases, which at the commencement date, have a lease term of 12 months or less.
(3)(2)Includes costs incurred by the Company for the right to use an underlying asset that vary because of changes in facts or circumstances occurring after the commencement date, other than the passage of time.

As part of the Company’s continued cost savings initiatives, the Company is actively looking to terminate or sublease certain office spaces and call centers. These actions resulted in a $2.7 millionno operating lease impairment chargecharges for the three and six months ended June 30, 2023March 31, 2024 and a $25.0 million operating lease impairment charge for the three and six months ended June 30, 2022.2023. Refer to Note 2. “Fair Value Measurements” for further details.
As of June 30, 2023,March 31, 2024, future minimum lease payments for operating leases consisted of the following:
(in thousands)Operating Leases
Remainder of 2023$5,454 
20248,026 
20256,703 
20265,528 
20275,683 
Thereafter26,279 
Total lease payments$57,673 
Less: Imputed interest(15,674)
Present value of lease liabilities$41,999 
GoHealth, Inc.2024 Form 10-Q  20


(in thousands)Operating Leases
Remainder of 2024$6,904 
20258,846 
20267,762 
20278,008 
20287,033 
Thereafter20,445 
Total lease payments$58,998 
Less: Imputed interest(15,491)
Present value of lease liabilities$43,507 
Supplemental cash flow information related to leases are as follows:
Three months ended Mar. 31,
(in thousands)20242023
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases$2,763 $3,343 
GoHealth, Inc.
2023 Form 10-Q  22


Three months ended Jun. 30,Six months ended Jun. 30,
(in thousands)2023202220232022
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases$3,705 $2,054 $7,048 $3,886 
Operating lease assets obtained in exchange for new lease obligations:
Operating lease assets obtained in exchange for new lease obligations(1)
$— $26,405 $— $26,405 
Reduction in operating lease ROU assets and lease liabilities due to reassessment of lease terms$— $4,155 $— $4,155 
(1)On May 12, 2020, the Company entered into a lease agreement with Wilson Tech 5, LLC, for a proposed site in Lindon, Utah, which commenced on June 8, 2022.
The weighted average remaining operating lease term and discount rate are as follows:
Jun. 30,
20232022
Weighted average remaining lease term (in years):7.6 years7.5 years
Weighted average discount rate:8.1 %8.0 %
Mar. 31,
20242023
Weighted average remaining lease term (in years)7.0 years7.6 years
Weighted average discount rate9.0 %8.1 %
11. COMMITMENTS AND CONTINGENCIES
Legal Proceedings

In September 2020, three purported securities class action complaints were filed in the United StatesU.S. District Court for the Northern District of Illinois against the Company, certain of its officers and directors, and certain underwriters, private equity firms and investment vehicles alleging that the Registration Statement filed in connection with the IPO was negligently prepared and, as a result, contained untrue statements of material fact, omitted material facts necessary to make the statements contained therein not misleading and failed to make necessary disclosures required under the rules and regulations governing its preparation, including the Securities Act of 1933 (the “Securities Class Action”). Compensatory damages and reasonable costs and expenses incurred in the Securities Class Action were sought by the plaintiffs. On December 10, 2020, the court in the earliest filed action consolidated the three complaints, appointed lead plaintiffs and lead counsel for the consolidated action, and captioned the consolidated action “In re GoHealth, Inc. Securities Litigation.” On February 25, 2021, lead plaintiffs filed a consolidated complaint. On April 26, 2021, the Company and officer and director defendants filed a motion to dismiss the complaint. On April 5, 2022, that motion was denied. On May 31, 2022, the Company and officer and director defendants filed an answer to the consolidated complaint and, on June 21, 2022, they filed an amended answer. On September 23, 2022, lead plaintiffs filed a motion for class certification, which remains pending. The court has not yet set a trial date.been decided. In December 2023, the parties notified the court that they had reached an agreement in principle to settle the Securities Class Action. On February 7, 2024, the plaintiffs filed an application with the court seeking preliminary approval of the parties’ proposed settlement, which application was granted by the court on February 27, 2024. The terms of the parties’ proposed settlement agreement are contained in the settlement documents filed with the court on February 7, 2024. The settlement, if finally approved by the Court, will fully resolve the Securities Class Action. A hearing for final approval of the settlement is scheduled for May 22, 2024.

On May 19, 2021, a derivative action (the “Derivative Action”) was filed in the United StatesU.S. District Court for the Northern District of Illinois, purportedly on behalf of the Company and against certain of the Company’s officers and directors, alleging breaches of fiduciary duty and other claims, based on substantially the same factual allegations as in the Securities Class Action. On June 6, 2022, the Derivative Action was stayed pursuant to the parties’ stipulation.

The Company disputes each claimproposed settlement in the above referenced matters and intends to defend the pending actions noted above. The ultimate outcome of any damages that may become payable if its defense is unsuccessful in whole or in part is not probable nor estimable at this time. While the Company feels confident in its defense of these pending matters, there can be no assurance that it will prevail and that any damages that may be awarded will not be material to the results of operations or financial condition of the Company. We are contesting the Securities Class Action andwill not resolve the Derivative Action. The Company is contesting the Derivative Action, but may pursue settlement negotiations, in one or both cases, as we deemit deems appropriate.

Although outcomes of these cases are uncertain until final disposition, the Company establishes an accrual for such mattermatters when a loss is deemed to be probable and reasonably estimable. To date, theThe Company haspreviously disclosed that it recorded a $12.0 million accrual for the Securities Class Action and the Derivative Action. TheOn March 13, 2024, the Company paid $10.5 million toward the Securities Class Action settlement. This payment was the remaining amount of the accrual is an estimateretention amount for which the Company was responsible under its applicable directors and is based onofficers liability insurance policies. The Company does not expect to
GoHealth, Inc.2024 Form 10-Q  21


make any further contribution to the settlement amount in the Securities Class Action. The remaining settlement amount waspaid by the Company’s understandinginsurance carriers under the applicable insurance policies and pursuant to the terms of the action, the specifics of the case and management’s best estimate of the potential loss to be incurred at this time. This estimate will be adjusted from time to time to reflect any changes in circumstances.proposed settlement. It is possible that actual future losses related to the Securities Class Action, andto the extent the Court does not approve the proposed settlement, or the Derivative Action, will exceed the current accrual level.
12. RELATED PARTY TRANSACTIONS

The Company is party to various lease agreements with 214 W Huron LLC, 220 W Huron Street Holdings LLC, 215 W Superior LLC and Wilson Tech 5, LLC, each of which areis controlled by significant shareholders of the Company, to lease its former corporate offices in Chicago, Illinois.Illinois and offices in Lindon, Utah. The Company pays rent, operating expenses, maintenance and utilities under the terms of the leases. For both the three and six months ended June 30,March 31, 2024 and 2023 the Company made aggregate lease payments of $1.5 million and $2.9
GoHealth, Inc.2023 Form 10-Q  23


million, respectively. For the three and six months ended June 30, 2022 the Company made aggregate lease payments of $0.7 million and $1.0 million, respectively.million.
On January 1, 2020, the Company entered into a non-exclusive aircraft dry lease agreement with an entity wholly-owned and controlled by certain significant shareholders of the Company. The agreement allows the Company to use an aircraft owned by this entity for business and on an as-needed basis. The agreement has no set term and is terminable without cause by either party upon 30 days’ prior written notice. Under the agreement, the Company is required to pay $6,036.94 per flight hour for use of the aircraft. For the three and six months ended June 30,March 31, 2024 and 2023 the Company recorded no expense under the lease. ForThe lease will terminate in the three and six months ended June 30, 2022 the Company recorded $0.2 million and $0.6 million, respectively, under the lease.second quarter of fiscal year 2024.
13. RESTRUCTURING COSTS
During the second and third quarters of fiscal year 2022, the Company implemented restructuring initiatives as part of its strategic transformation to drive efficiency and optimize costs. On June 3, 2022, the Board approved the separation and replacement of key management roles, including Chief Operating Officer, Chief Financial Officer, Chief Strategy Officer, and President. On August 9, 2022, the Company eliminated 828 full-time positions, representing approximately 23.7% of the workforce, primarily within the customerconsumer care and enrollment group. The majority of the restructuring charges incurred relate to employee termination benefits and will be settled in cash through the second quarter of 2024. The restructuring activities related to this plan were materially complete as of December 31, 2022. The Company evaluates restructuring charges in accordance with ASC 420 Exit or Disposal Cost Obligations and ASC 712 Compensation—Nonretirement Post-Employment Benefits.
The Company incurred no restructuring and other related charges during the three and six months ended June 30, 2023March 31, 2024 and 2022.2023.
The following table provides the changes in the Company’s restructuring and other related charges that will be settled in cash, included in accrued liabilities on the Condensed Consolidated Balance Sheets:
(in thousands)Restructuring charges
Balance at January 1, 2023$2,083 
Charges incurred— 
Cash paid(826)
Balance at June 30, 2023$1,257
Mar. 31,
(in thousands)20242023
Beginning balance$645 $2,083 
Charges incurred— — 
Cash paid(281)(379)
Ending balance$364 $1,704 
GoHealth, Inc.20232024 Form 10-Q  2422


ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITIONS AND RESULTS OF OPERATIONS.

This section presents management’s perspective on our financial condition and results of operations. The following discussion and analysis is intended to highlight and supplement data and information presented elsewhere in this Quarterly Report on Form 10-Q, including the Condensed Consolidated Financial Statements and related Notes, and should be read in conjunction with the accompanying tables. To the extent that this discussion describes prior performance, the descriptions relate only to the periods listed, which may not be indicative of our future financial outcomes. In addition to historical information, this discussion contains forward-looking statements that involve risks, uncertainties and assumptions that could cause results to differ materially from management’s expectations. Factors that could cause such differences are discussed underin the headingsection titled “Cautionary Note Regarding Forward-Looking Statements” in this Quarterly Report on Form 10-Q, and under the heading “Item 1A.sections titled “Cautionary Note Regarding Forward-Looking Statements,” “Summary Risk Factors.”Factors” and “Risk Factors” in the 2022our 2023 Annual Report on Form 10-K. The risks and uncertainties described in the 2022our 2023 Annual Report on Form 10-K are not the only onesrisks and uncertainties we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also materially adversely affect our business, financial condition, or results of operations. We assume no obligation to update any of these forward-looking statements.
Unless otherwise noted, all dollars are in thousands. In certain cases, numbers and percentages in the tables below may not foot due to rounding.
Overview

We are a leading health insurance marketplace and Medicare-focused digital health company whose missionpurpose is to improve access tocompassionately ensure consumers’ peace of mind when making healthcare in America. Our proprietary technology platform leverages modern machine-learning algorithms powered by nearly two decades of insurance behavioral data to reimagine the optimal process for helping individuals find the best health insurance plan for their specific needs. Our differentiated combination ofdecisions so they can focus on living life. With a vertically integrated consumer acquisitionwidely scalable end-to-end platform and highly skilled and trained agents has enabled us to enroll millions of people in Medicare and individual and family plans since our inception. With a current commissionable market of nearly $30 billion, over 10,000 Americans turning 65 years old every day and our significantsubstantial presence in the Medicare space,landscape, we believe we will continueare uniquely positioned as a trusted partner to be one of the top choices for insurance advice to help65 million Medicare-eligible Americans, as well as the 11,000 Americans becoming eligible each day, as they navigate one of thelife's most important purchasing decisions individuals make.decisions. For many of these consumers, enrolling in a health insurance plan is confusing and difficult and seemingly small differences between health plans may lead to significant out-of-pocket costs or lack of access to critical providers and medicines. We aim to simplify the process by offering education, comparison guidance, transparency and choice. This includes providing a large selection of leading health plan choices, advice informed by consumers’ specific needs, transparency of health plan benefits and fit, assistance accessing available government subsidies and a high-touch consumer care team. We partner with health plans across the nation that provide access to high quality health plans across all 50 states.
Update on Business Trends and Strategy
The Company is part of
GoHealth has evolved from a dynamic markettraditional Medicare enrollment company to a Medicare engagement company, focusing on forging high-quality relationships with our consumers. This shift emphasizes a more integrated and as expectations evolve, the Company likewise worksinteractive approach to evolve in parallel its business strategiesconsumer care and priorities. In response to the pressures on LTVs in 2021 and 2022 that we previously observed and discussed, the Company focused its efforts on delivering efficiency, with an emphasis on operational efficiency as opposed to revenue maximization. As a result, in 2022 we implemented steps to transition to thereflects how our Encompass operating model, which is our preferrednow operating platform thatat scale with all key health plan partners, puts the customerconsumer at the center of all our activities including how we market, support enrollment activities, provide administrative services, utilize our proprietary technology and ultimately deliver a high qualityhigh-quality solution to those we serve. The Encompass model supports all Medicare services, including agency and non-agency revenue. Agency revenue refers to the commission revenue and partner marketing revenue the Company receives when GoHealth agents or the Company’s independent network of outsourced agents enroll the consumer and submit the policy application to the health plan partner, becoming the agent of record. Non-agency revenue refers to services provided by the Company that support enrollment and engagement activities in which the Company is not the agent of record. The non-agency model moves away from the agency structure in that cash is collected in advance or in close proximity to the point in time revenue is recognized, and was previously labeled “Encompass Revenue.”
We refined the size of our sales force to align with our focus on quality, and we expanded our services by offering Encompass Connect and Encompass Engage to our health plan partner members. Encompass Connect is designed to focus on consumer acquisition and to provide enrollment related services to our participating health plan partners. Using machine learning technology, our agents aim to effectively qualify and match individuals with the best plan. This combination of technology and experienced agents delivers a personalized matching process that incorporates consumers’ top priorities and helps them to understand associated tradeoffs across various benefits as they select and enroll in a plan. During the second quarter of 2023, we expanded our Encompass Connect contracts and model to include our external partners.
Encompass Engage includes post-enrollment member outreach and engagement services. Our agents strive to alleviate the confusion that consumers often feel by facilitating an onboarding experience customized to a member’s plan and health needs.

With leading proprietary technology and consumer insights,believe our end-to-end Encompass model offers a differentiated way for Medicare beneficiaries to navigate the complex Medicare Advantage plan selection process and begin to utilize their new plan benefits with greater confidence. By working closely

The Encompass operating model supports all Medicare services, including agency and non-agency revenue. Agency revenue refers to the commission revenue and partner marketing and other revenue we receive when GoHealth agents or our independent network of outsourced agents enroll the consumer and submit the policy application to the health plan partner, becoming the agent of record. Non-agency revenue refers to services we provide that support enrollment and engagement activities in which GoHealth is not the agent of record. During the second quarter of 2023 we began offering these enrollment and engagement services to our external partners, which we refer to as our vConnect program. The non-agency model moves away from the agency structure in that cash is collected in advance or in close proximity to the point in time revenue is recognized.

The enrollment and engagement services offered through our non-agency model are strategically designed to enhance the consumer experience, reflecting our focus on building trusted, long-term relationships with our benefit consultantsconsumers. The growth of non-agency revenue period over period is a reflection of our evolution from a traditional Medicare enrollment company to a Medicare engagement company. For the three months ended March 31, 2024, non-agency revenue increased by $40.9 million compared to the prior year period. Non-agency revenue grew from 27% of total Medicare revenue for the three months ended March 31, 2023 to 46% of total Medicare revenue for the three months ended March 31, 2024.

We continue to refine our Encompass operating model through investments in technology. Last year, we introduced PlanFit CheckUp, utilizing analytics from nearly thirty million consumer touchpoints and dedicated health plan enrollment specialists, we believe individuals can better understand the plan options available and receive more detailed, plan-specific information during the enrollment process. Coupledmachine learning to help our licensed agents accurately match consumers with the executionbest Medicare plans for their needs. PlanFit CheckUp enables consumers to regularly assess the appropriateness of our new member onboarding action plans, consumers who enrolltheir current plan through our Encompass model have exhibited higher customer persistency.

a data-driven customized process, guided by the trusted expertise of a licensed GoHealth agent. In addition to further developing PlanFit Checkups, we are investing in technologies like Customer 360.
GoHealth, Inc.20232024 Form 10-Q  2523


Customer 360 provides a unified view of the consumer across every touchpoint to ensure high-quality, personalized service at every point of the consumer journey.

In the 2023 AEP we observed a unique set of market dynamics where for the first time in recent years the health plans on average made very little change to benefits, with many reducing benefits for the average Medicare consumer. As a result we observed higher shopping but lower switching. In response to these observed market dynamics, we enhanced our targeted marketing efforts to identify consumers in need of new health plan options.

The introduction of the Centers for Medicare and Medicaid Services (“CMS”) Final 2025 Marketing Rule in April 2024 has implications for Medicare Advantage plans, potentially affecting benefit structures and necessitating more dynamic consumer shopping behaviors. As the landscape becomes more complex, we believe GoHealth’s role as a reliable guide becomes increasingly critical. We are analyzing the implications of the CMS Final Rule with our health plan partners and closely monitoring its effects on the Medicare landscape. Further discussion of how changes and developments in the laws and regulations governing the health insurance markets in the U.S. could materially affect our business, operating results, financial condition and qualified prospects is included under the heading “Item 1A. Risk Factors” in our 2023 Annual Report on Form 10-K.

Additionally, the Company made the strategic decision to exit its non-EncompassNon-Encompass BPO Services, or services in which we dedicate certain agents to specific health plan partners and agencies outside of the Encompass model, to focus on our core business. The exit was completed during the second quarter of 2023. During the three and six months ended June 30,March 31, 2024 and 2023, non-EncompassNon-Encompass BPO Services contributed $2.5 millionzero and $9.3 million of net revenue, respectively. During the three and six months ended June 30, 2022, non-Encompass BPO Services contributed $23.1 million and $58.1$6.8 million of net revenue, respectively.

During the first quarter of 2023, the Company reorganized its operations from four operating and reportable segments to one operating and reportable segment. The change reflects how the CODM evaluates the Company’s operating and financial performance on a consolidated basis and is consistent with changes made to the Company’s internal reporting structure. Additionally, the single operating segment aligns with the Company’s shift in focus towards Medicare products. All prior period comparative segment information was recast to reflect the current single operating segment in accordance with ASC 280, Segment Reporting.

Ownership
GoHealth, Inc. is the sole managing member of GHH, LLC. Although we have a minority economic interest in GHH, LLC, we have the sole voting interest in, and control of the business and affairs of, GHH, LLC and its direct and indirect subsidiaries. As a result, GoHealth, Inc. consolidates GHH, LLC and records significant non-controlling interest in a consolidated entity in GoHealth, Inc.’s Condensed Consolidated Financial Statements for the economic interest in GHH, LLC held directly or indirectly by the Continuing Equity Owners. The weighted average ownership percentages for the applicable reporting periods are used to attribute net income (loss) and other comprehensive income (loss) to the Company and the non-controlling interest holders. The non-controlling interest holders' weighted average ownership percentagespercentage for the three and six months ended June 30,March 31, 2024 and 2023 was 58.8%56.8% and 59.0%, respectively. The non-controlling interest holders' weighted average ownership percentages for the three and six months ended June 30, 2022 were 61.5% and 62.6%59.3%, respectively.
The percentage ownership of total shares of Class A and Class B common stock issued and outstanding as of June 30, 2023,March 31, 2024, is as follows:
10051115
The percentage of ownership noted above is inclusive of only Class A and Class B common stock issued and outstanding. It does not include the Series A redeemable convertible preferred stock or the impact of any conversion of such, should a conversion occur. For more information on the Series A redeemable convertible preferred stock, please refer to Note 55. “Stockholders' Equity” of the Notes to Condensed Consolidated Financial Statements.
The Company implemented the Reverse Stock Split, which became effective on November 17, 2022. Please refer to Note 5 “Stockholders' Equity” of the Notes to Condensed Consolidated Financial Statements for more information on the Reverse Stock Split.
GoHealth, Inc. is subject to U.S. federal, state and local income taxes with respect to our allocable share of any taxable income of GHH, LLC and is taxed at the prevailing corporate tax rates. In addition to tax expenses, we also incur expenses related to our status as a public company, plus payment obligations under the Tax Receivable Agreement (“TRA”), which could be significant. We intend to cause GHH, LLC to make distributions to us in an amount sufficient to allow us to pay these expenses and fund any payments due under the TRA.
GoHealth, Inc.20232024 Form 10-Q  2624


Results of Operations
The following is our consolidated results of operations for the three and six months ended June 30, 2023March 31, 2024 and 2022:2023:
Three months ended Jun. 30,Six months ended Jun. 30,
Three months ended Mar. 31,
Three months ended Mar. 31,
Three months ended Mar. 31,
(in thousands)(in thousands)2023202220232022
(in thousands)
(in thousands)
Net revenues
Net revenues
Net revenuesNet revenues142,779 158,654 325,937  429,247 
Operating expenses:Operating expenses:
Operating expenses:
Operating expenses:
Revenue share
Revenue share
Revenue shareRevenue share36,422 51,074 81,884 118,997 
Marketing and advertisingMarketing and advertising39,269 44,714 85,012 128,747 
Customer care and enrollment45,536 66,542 87,563 144,997 
Marketing and advertising
Marketing and advertising
Consumer care and enrollment
Consumer care and enrollment
Consumer care and enrollment
Technology
Technology
TechnologyTechnology10,511 10,749 20,054 23,508 
General and administrativeGeneral and administrative37,855 38,106 60,473 67,323 
General and administrative
General and administrative
Amortization of intangible assetsAmortization of intangible assets23,515 23,515 47,029 47,029 
Operating lease impairment charges2,687 24,995 2,687 24,995 
Amortization of intangible assets
Amortization of intangible assets
Total operating expenses
Total operating expenses
Total operating expensesTotal operating expenses195,795 259,695 384,702  555,596 
Income (loss) from operationsIncome (loss) from operations(53,016)(101,041)(58,765)— (126,349)
Income (loss) from operations
Income (loss) from operations
Interest expense
Interest expense
Interest expenseInterest expense17,265 12,724 34,156 24,122 
Other (income) expense, netOther (income) expense, net21 (13)(32)50 
Other (income) expense, net
Other (income) expense, net
Income (loss) before income taxesIncome (loss) before income taxes(70,302)(113,752)(92,889)(150,521)
Income tax expense (benefit)(73)— (117)472 
Income (loss) before income taxes
Income (loss) before income taxes
Income tax (benefit) expense
Income tax (benefit) expense
Income tax (benefit) expense
Net income (loss)
Net income (loss)
Net income (loss)Net income (loss)(70,229)(113,752)(92,772)(150,993)
Net income (loss) attributable to non-controlling interestsNet income (loss) attributable to non-controlling interests(41,287)(69,933)(54,651)(93,691)
Net income (loss) attributable to non-controlling interests
Net income (loss) attributable to non-controlling interests
Net income (loss) attributable to GoHealth, Inc.
Net income (loss) attributable to GoHealth, Inc.
Net income (loss) attributable to GoHealth, Inc.Net income (loss) attributable to GoHealth, Inc.$(28,942)$(43,819)$(38,121)$(57,302)
Non-GAAP financial measures:Non-GAAP financial measures:
Non-GAAP financial measures:
Non-GAAP financial measures:
EBITDA
EBITDA
EBITDAEBITDA$(26,669)$(74,617)$(6,098)$(74,040)
Adjusted EBITDAAdjusted EBITDA$788 $(31,741)$29,566 $(20,668)
Adjusted EBITDA
Adjusted EBITDA
Adjusted EBITDA marginAdjusted EBITDA margin0.6 %(20.0)%9.1 %(4.8)%
Adjusted EBITDA margin
Adjusted EBITDA margin
The following is our net revenues for the three and six months ended June 30, 2023March 31, 2024 and 2022:2023:
Net RevenuesThree months ended Jun. 30,
20232022$ Change% Change
$142,779 $158,654 $(15,875)(10.0)%
Six months ended Jun. 30,
20232022$ Change% Change
$325,937 $429,247 $(103,310)(24.1)%
Net RevenuesThree months ended Mar. 31,
20242023$ Change% Change
$185,600 $183,158 $2,442 1.3 %
The decreaseincrease for the three months ended June 30, 2023March 31, 2024 compared to the prior year period was primarily attributable to an increase in non-agency revenue, which includes the enrollment and engagement services offered through the Encompass Connect and Encompass Engage programs, partially offset by a decrease in agency revenue driven by a decline in Submissions for which GoHealth is the agent of record. The increase was further offset by a decrease in revenues associated with the strategic decision to exit our non-EncompassNon-Encompass BPO services (services inServices, which we dedicate certain agents to specific health plan partners and agencies outsidewas completed during the second quarter of the Encompass model), to focus on our core business. The decrease was partially offset by a 4%, increase in Medicare revenue. The decrease for the six months ended June 30, 2023 compared to the prior year period was primarily attributable to a decrease in agent headcount and associated opportunities, which drove a 16% decrease in Medicare revenue, as well as a decrease in revenues associated with the strategic decision to exit our non-Encompass BPO services.2023.
The following are our key components of operating expenses and results thereof for the three and six months ended June 30, 2023March 31, 2024 and 2022:2023:
Revenue shareThree months ended Jun. 30,% of Net Revenues
20232022$ Change% Change20232022
$36,422 $51,074 $(14,652)(28.7)%25.5%32.2%
Six months ended Jun. 30,% of Net Revenues
20232022$ Change% Change20232022
$81,884 $118,997 $(37,113)(31.2)%25.1%27.7%
Revenue shareThree months ended Mar. 31,% of Net Revenues
20242023$ Change% Change20242023
$38,013 $45,462 $(7,449)(16.4)%20.5%24.8%
GoHealth, Inc.2023 Form 10-Q  27


The decrease for the three months ended June 30, 2023March 31, 2024 compared to the prior year period was primarily attributable to declines in certain direct partner campaigns with revenue-sharing components. The decrease for the six months ended June 30, 2023 was primarily attributable to declines in certain direct partner campaigns with revenue-sharing components as well asdriven by a decrease in Submissions generated by our independent network of outsourced agents,, which decreased the amount of expense we recognized pursuant to our revenue-sharing agreements.agreements with our external partners. The decrease was partially offset by the launch of the vConnect program during the second quarter of 2023, which includes revenue-sharing components.
Marketing and advertising expenseThree months ended Mar. 31,% of Net Revenues
20242023$ Change% Change20242023
$52,775 $45,743 $7,032 15.4 %28.4%25.0%

Marketing and advertising expenseThree months ended Jun. 30,% of Net Revenues
20232022$ Change% Change20232022
$39,269 $44,714 $(5,445)(12.2)%27.5%28.2%
Six months ended Jun. 30,% of Net Revenues
20232022$ Change% Change20232022
$85,012 $128,747 $(43,735)(34.0)%26.1%30.0%
GoHealth, Inc.2024 Form 10-Q  25


The decreases for both the three and six months ended June 30, 2023 compared to the prior year periods were primarily attributable to an intentional pullback on marketing and advertising spend as the Company focused on higher quality Submissions through targeted marketing.
Customer care and enrollmentThree months ended Jun. 30,% of Net Revenues
20232022$ Change% Change20232022
$45,536 $66,542 $(21,006)(31.6)%31.9%41.9%
Six months ended Jun. 30,% of Net Revenues
20232022$ Change% Change20232022
$87,563 $144,997 $(57,434)(39.6)%26.9%33.8%
The decrease for both the three and six months ended June 30, 2023 compared to the prior year periods were primarily attributable to reduced agent headcount as we focused on improving operational efficiencies.
Technology expenseThree months ended Jun. 30,% of Net Revenues
20232022$ Change% Change20232022
$10,511 $10,749 $(238)(2.2)%7.4%6.8%
Six months ended Jun. 30,% of Net Revenues
20232022$ Change% Change20232022
$20,054 $23,508 $(3,454)(14.7)%6.2%5.5%
The slight decreaseincrease for the three months ended June 30, 2023March 31, 2024 compared to the prior year period was primarily attributable to enhancements in our targeted marketing efforts to identify consumers in need of new health plan options as well as an intentional pullback on marketing and advertising spend during the prior year period, partially offset by a ramp updecline in hiring withinpayments to our external marketing partners.
Consumer care and enrollmentThree months ended Mar. 31,% of Net Revenues
20242023$ Change% Change20242023
$47,861 $42,027 $5,834 13.9 %25.8%22.9%
The increase for the three months ended March 31, 2024 was primarily attributable to an increased agent headcount compared to the prior year period.
Technology expenseThree months ended Mar. 31,% of Net Revenues
20242023$ Change% Change20242023
$10,550 $9,543 $1,007 10.6 %5.7%5.2%
The increase for the three months ended March 31, 2024 was primarily attributable to an increased headcount in our technology support functions compared to the prior year period as we continue to invest in and enhance our technology to drive overall efficiency in our modelEncompass workflow and improve the consumer experience, despite an overall reduced headcount compared to the prior year period. experience.
General and administrative expenseThree months ended Mar. 31,% of Net Revenues
20242023$ Change% Change20242023
16,919 22,618 $(5,699)(25.2)%9.1%12.3%
The decrease for the sixthree months ended June 30, 2023March 31, 2024 compared to the prior year period was primarily attributable to reduced headcounta decrease in our technology support functions.
General and administrative expenseThree months ended Jun. 30,% of Net Revenues
20232022$ Change% Change20232022
37,855 38,106 $(251)(0.7)%26.5%24.0%
Six months ended Jun. 30,% of Net Revenues
20232022$ Change% Change20232022
$60,473 $67,323 $(6,850)(10.2)%18.6%15.7%
The decrease for the three months ended June 30, 2023 compared to the prior year period was primarily attributable to reduced headcount in our corporate infrastructure, partially offset by an increase in expenses related to legal fees. The decrease for the six months ended June 30, 2023 compared to the prior year period was primarily attributable to reduced headcount in our corporate infrastructure as well asshare-based compensation expense and a reduction of expenses related to consulting and professional services, partially offset by an increase in expenses related to legal fees.
GoHealth, Inc.2023 Form 10-Q  28


Amortization of intangible assetsThree months ended Jun. 30,% of Net Revenues
20232022$ Change% Change20232022
23,515 23,515 $— — %16.5%14.8%
Six months ended Jun. 30,% of Net Revenues
20232022$ Change% Change20232022
$47,029 $47,029 $— — %14.4%11.0%
Amortization of intangible assetsThree months ended Mar. 31,% of Net Revenues
20242023$ Change% Change20242023
23,514 23,514 $— — %12.7%12.8%
Amortization of intangible assets expense was $23.5 million for both the three and six months ended June 30, 2023March 31, 2024 and 2022, and2023. Amortization of intangible assets expense relates to the amortization of developed technology and customer relationships.
Interest expenseThree months ended Jun. 30,% of Net Revenues
20232022$ Change% Change20232022
17,265 12,724 $4,541 35.7 %12.1%8.0%
Six months ended Jun. 30,% of Net Revenues
20232022$ Change% Change20232022
$34,156 $24,122 $10,034 41.6 %10.5%5.6%
Interest expenseThree months ended Mar. 31,% of Net Revenues
20242023$ Change% Change20242023
17,951 16,891 $1,060 6.3 %9.7%9.2%
The increasesincrease for both the three and six months ended June 30, 2023March 31, 2024 compared to the prior year periods wereperiod was primarily attributable to an increase in interest rates on our Term Loan Facilities.

Non-GAAP Financial Measures
We use supplemental measures of our performance that are derived from our consolidated financial information but which are not presented in our Condensed Consolidated Financial Statements prepared in accordance with GAAP. These non-GAAP financial measures include net income (loss) before interest expense, income tax (benefit) expense and depreciation and amortization expense, or EBITDA; Adjusted EBITDA; Adjusted EBITDA margin; Cash Adjusted EBITDA; Sales per Submission; Cost per Submission and Adjusted Gross Margin per Submission. Adjusted EBITDA is the primary financial performance measure used by management to evaluate the business and to monitor its results of operations. Cash Adjusted EBITDA is used by management to assess Adjusted EBITDA excluding the effect of LTV estimates period over period. Sales per Submission, Cost per Submission and Adjusted Gross Margin per Submission are key operating metrics used by management to understand the Company’s underlying financial performance and trends.
Adjusted EBITDA represents, as applicable for the period, EBITDA as further adjusted for certain items summarized in the table furnished below. Adjusted EBITDA margin represents Adjusted EBITDA divided by net revenue.revenues. Cash Adjusted EBITDA represents Adjusted EBITDA plus a decrease or less an increase in the period over period change in our net contract assets. Sales per Submission represents Medicare Revenue per Submission as further adjusted for certain items summarized in the table furnished below within the Key Business Performance and Operating Metrics section below.section. Cost per Submission represents Operating Expense per Submission as further adjusted for certain items summarized in the table furnished below within the Key
GoHealth, Inc.2024 Form 10-Q  26


Business Performance and Operating Metrics section below.section. Adjusted Gross Margin per Submission represents Sales per Submission less Cost per Submission.
We use non-GAAP financial measures to supplement financial information presented on a GAAP basis. We believe that excluding certain items from our GAAP results allows management to better understand our consolidated financial performance from period to period and better project our future consolidated financial performance as forecasts are developed at a level of detail different from that used to prepare GAAP-based financial measures. Moreover, we believe these non-GAAP financial measures provide our stakeholders with useful information to help them evaluate our operating results by facilitating an enhanced understanding of our operating performance and enabling them to make more meaningful period to period comparisons. Adjusted EBITDA is used as a basis for certain compensation programs sponsored by the Company. There are limitations to the use of the non-GAAP financial measures presented in this Quarterly Report on Form 10-Q. For example, our non-GAAP financial measures may not be comparable to similarly titled measures of other companies. Other companies, including companies in our industry, may calculate non-GAAP financial measures differently than we do, limiting the usefulness of those measures for comparative purposes.
The non-GAAP financial measures are not meant to be considered as indicators of performance in isolation from or as a substitute for net income (loss)the most directly comparable measures prepared in accordance with GAAP, and should be read only in conjunction with financial information presented on a GAAP basis. Reconciliations of each of EBITDA, Adjusted EBITDA, Cash Adjusted EBITDA, Sales per Submission, Cost per Submission and Adjusted Gross Margin per Submission to its most directly comparable GAAP financial measure are presented in the tables below in this Quarterly Report on Form 10-Q. We encourage you to review the reconciliations in conjunction with the presentation of the non-GAAP financial measures for each of the periods presented. In future periods, we may exclude similar items, may incur income and expenses similar to these excluded items and may include other expenses, costs and non-recurringnon-routine items.
GoHealth, Inc.2023 Form 10-Q  29


The following table sets forth the reconciliations of GAAP net income (loss) to EBITDA and Adjusted EBITDA for the periods presented:
Three months ended Jun. 30,Six months ended Jun. 30,
Three months ended Mar. 31,
Three months ended Mar. 31,
Three months ended Mar. 31,
Non-GAAP Financial Measures
Non-GAAP Financial Measures
Non-GAAP Financial MeasuresNon-GAAP Financial Measures2023202220232022
Net revenuesNet revenues$142,779 $158,654 $325,937 $429,247 
Net revenues
Net revenues
Net income (loss)
Net income (loss)
Net income (loss)Net income (loss)(70,229)(113,752)(92,772)(150,993)
Interest expenseInterest expense17,265 12,724 34,156 24,122 
Interest expense
Interest expense
Income tax expense (benefit)
Income tax expense (benefit)
Income tax expense (benefit)Income tax expense (benefit)(73)— (117)472 
Depreciation and amortization expenseDepreciation and amortization expense26,368 26,411 52,635 52,359 
Depreciation and amortization expense
Depreciation and amortization expense
EBITDAEBITDA(26,669)(74,617)(6,098)(74,040)
Share-based compensation expense (1)10,120 14,257 16,704 19,412 
EBITDA
EBITDA
Share-based compensation expense (benefit)(1)
Share-based compensation expense (benefit)(1)
Share-based compensation expense (benefit)(1)
Legal fees (2)Legal fees (2)12,730 — 14,353 — 
Operating lease impairment charges (3)2,687 24,995 2,687 24,995 
Severance costs (4)1,920 3,624 1,920 5,015 
Professional services (5)— — — 3,950 
Legal fees(2)
Legal fees(2)
Severance costs(3)
Severance costs(3)
Severance costs(3)
Adjusted EBITDA
Adjusted EBITDA
Adjusted EBITDAAdjusted EBITDA$788 $(31,741)$29,566 $(20,668)
Adjusted EBITDA MarginAdjusted EBITDA Margin0.6 %(20.0)%9.1 %(4.8)%
Adjusted EBITDA Margin
Adjusted EBITDA Margin

(1)Represents non-cash share-based compensation expense (benefit) relating to equity awards as well as share-based compensation expense (benefit) relating to liability classified awards that will be settled in cash.
(2)Represents legal fees, settlement accruals and other expenses related to certain litigation, Credit Agreement amendments and other non-routine legal feesor regulatory matters as described in Note 4. “Long-Term Debt” and accruals unrelatedNote 11. “Commitments And Contingencies” of the Notes to our core operations.Condensed Consolidated Financial Statements.
(3)Represents operating lease impairment charges, reducing the carrying value of the associated ROU assets and leasehold improvements to the estimated fair values.
(4)Representsseverance costs associated with the termination of executive employment and associated fees unrelated to restructuring activities.
(5)Represents costs associated with non-recurring consulting fees and other professional services.a reduction in workforce.

Adjusted EBITDAThree months ended Jun. 30,% of Net Revenues
20232022$ Change% Change20232022
$788 $(31,741)$32,529 (102.5)%0.6 %(20.0)%
Six months ended Jun. 30,% of Net Revenues
20232022$ Change% Change20232022
$29,566 $(20,668)$50,234 (243.1)%9.1 %(4.8)%
Adjusted EBITDAThree months ended Mar. 31,% of Net Revenues
20242023$ Change% Change20242023
$26,894 $28,778 $(1,884)6.5 %14.5 %15.7 %

The increasesdecrease for both the three and six months ended June 30, 2023March 31, 2024 compared to the prior year periods wereperiod was primarily due to our focus on driving high-quality Medicare services for our beneficiaries through the Encompass operating model. Our improved operating efficiencies were enabled by reduced headcount,investments in targeted marketing and enhancementsother operating expenses, partially offset by a decrease in revenue share and an increase in net revenues.



GoHealth, Inc.2024 Form 10-Q  27


The following table sets forth the reconciliations of Adjusted EBITDA to Cash Adjusted EBITDA for the periods presented:
Three months ended Mar. 31,
(in thousands)20242023
Adjusted EBITDA$26,894$28,778
Beginning commissions receivable911,6971,031,433
Beginning commissions payable(321,987)(375,141)
Beginning net contract assets589,710656,292
Ending commissions receivable843,127936,804
Ending commissions payable(296,549)(329,435)
Ending net contract assets546,578607,369
(Increase)/decrease in contract assets43,13248,923
Cash Adjusted EBITDA$70,026$77,701
Cash Adjusted EBITDAThree months ended Mar. 31,% of Net Revenues
20242023$ Change% Change20242023
$70,026 $77,701 $(7,675)9.9 %37.7 %42.4 %
Cash Adjusted EBITDA decreased compared to the prior year period because of a decrease in Adjusted EBITDA, as described above, and a decrease in cash collected from our proprietary technology.net contract assets as we continue to earn more non-agency revenue relative to agency revenue.
Key Business Performance and Operating Metrics
In addition to traditional financial metrics, we rely upon certain business and operating metrics to evaluate our business performance and facilitate our operations. Below are the most relevant business and operating metrics besides EBITDA and Adjusted EBITDA, for our single operating and reportable segment.segment, except for EBITDA, Adjusted EBITDA and Cash Adjusted EBITDA which are discussed above.
The following tables set forth the reconciliations of Medicare Revenue per Submission, Operating Expense per Submission, and Gross Margin per Submission to Sales per Submission, Cost Per Submission, and Adjusted Gross Margin per Submission for the periods indicated (unaudited):
GoHealth, Inc.2023 Form 10-Q  30


Three months ended Jun. 30,Six months ended Jun. 30,
2023202220232022
Sales per Submission
Medicare Revenue per Submission$852$865$819$879
Lookback Adjustments reported during the indicated periods1
2014
Sales per Submission$852$885$819$893
Cost per Submission
Operating Expense per Submission$1,202$1,677$1,022$1,337
Indirect operating expenses2
(458)(629)(346)(392)
Lookback Adjustments reported during the indicated periods1
64
Exit of non-Encompass BPO Services(14)(127)(21)(114)
Share-based compensation expense3
(5)(5)(4)(5)
Cost per Submission$725$922$651$830
Gross Margin per Submission4
$(350)$(812)$(203)$(458)
Adjusted Gross Margin per Submission5
$127$(37)$168$63
Three months ended Mar. 31,
20242023
Sales per Submission
Medicare Revenue per Submission$856$794
Sales per Submission$856$794
Cost per Submission
Operating Expense per Submission$877$884
Indirect operating expenses(1)
(235)(261)
Exit of Non-Encompass BPO Services(25)
Share-based compensation expense(2)
(2)(6)
Cost per Submission$640$592
Gross Margin per Submission(3)
$(21)$(90)
Adjusted Gross Margin per Submission(4)
$216$202

(1)Excludes the impact of Lookback Adjustments on non-Encompass BPO Services.
(2)Indirect operating expenses include technology, and general and administrative, expenses, inclusive of associated share-based compensation expense, as well as amortization of intangible assets, and operating lease impairment charges and restructuring and other related charges.
(3)(2)Shared-basedShare-based compensation expense included within marketing and advertising expenses and customerconsumer care and enrollment expenses.
(4)(3)Medicare Revenue per Submission less Operating Expense per Submission.
(5)(4)Sales per Submission less Cost per Submission.

Submissions
Submissions are counted when an individual either (i) completes an application with our licensed agent that is submitted to the health plan partner and subsequently approved by the health plan partner during the indicated period, excluding applications through our non-EncompassNon-Encompass BPO Services or (ii) is transferred by our agent to the health plan partner through the Encompass marketplace during the indicated period. Not all Submissions will go into effect, as some individuals may fail to enroll or once enrolled may switch out of a policy within the disenrollment period during the first 90 days of the policy.
GoHealth, Inc.2024 Form 10-Q  28


The following table presents the number of Submissions for the periods presented:
SubmissionsThree months ended Jun. 30,
20232022Change% Change
162,837 154,893 $7,944 5.1 %
Six months ended Jun. 30,
20232022Change% Change
$376,482 415,559 $(39,077)(9.4)%
SubmissionsThree months ended Mar. 31,
20242023Change% Change
216,148 213,645 2,503 1.2 %
The increase for the three months ended June 30, 2023March 31, 2024 compared to the prior year period was attributable to an increase in opportunities resulting from our focus on higher quality Submissions through targeted marketing. The decrease for the six months ended June 30, 2023 compared to the prior year period was primarily driven by a decreasemarketing efforts, as well as enhancements in agent headcounttraining, technology and associated opportunities resulting from our strategic focus on driving high-quality Medicare services and operational efficiencies.consumer retention strategies.
Sales Per Submission
Sales per Submission represents (x) the sum of (i) aggregate commissions estimated to be collected over the estimated life of all commissionable Submissions for the relevant period based on multiple factors, including but not limited to, contracted commission rates, health plan partner mix and expected policy persistency with applied constraints, excluding revenue adjustments recorded in the period, but relating to performance obligations satisfied in prior periods, (ii) Encompass revenue, and (iii) partner marketing and enrollment services, divided by (y) the number of Submissions for such period, as reported above. Aggregate commissions isare equal to the sum of the commission revenue due upon the initial sale of a policy, and when applicable, an estimate of future renewal commissions per commissionable Submissions, and this figure excludes commissions through our non-EncompassNon-Encompass BPO Services. The estimate of the future renewal commissions is determined by using the contracted renewal commission rates constrained by a persistency-adjusted renewal period. The persistency-adjusted renewal period is determined based on our historical experience and available industry and health plan partner historical data. Persistency-adjustmentsPersistency adjustments allow us to estimate renewal revenue only to the extent probable that a material reversal in revenue would not be expected to occur. These factors may result in varying values from period to period. Sales per Submission represents revenues only from policies sold during the period, but excludes policies originally submitted in prior periods.
GoHealth, Inc.2023 Form 10-Q  31


The following table presents the Sales per Submission for the periods presented:
Sales Per SubmissionThree months ended Jun. 30,
20232022$ Change% Change
$852 $885 $(33)(3.7)%
Six months ended Jun. 30,
20232022$ Change% Change
$819 $893 $(74)(8.3)%
Sales Per SubmissionThree months ended Mar. 31,
20242023$ Change% Change
$856 $794 $62 7.8 %
The decreasesincrease for both the three and six months ended June 30, 2023March 31, 2024 compared to the prior year periods were primarilyperiod was driven by a changean increase in health plan partner mix, as well as an increased constraint on agency commission, partially offset by improved effectuation.non-agency revenue, which includes the enrollment and engagement services offered through the Encompass Connect and Encompass Engage programs.
Sales/Cost of Submission and Cost Per Submission
Sales/Cost of Submission represents (x) the sum of (i) aggregate commissions estimated to be collected over the estimated life of all commissionable Submissions for the relevant period based on multiple factors, including but not limited to, contracted commission rates, health plan partner mix and expected policy persistency with applied constraints, excluding revenue adjustments recorded in the period, but relating to performance obligations satisfied in prior periods, and such expenses related to our non-EncompassNon-Encompass BPO Services, (ii) Encompass revenue, and (iii) partner marketing and enrollment services, divided by (y) the aggregate cost to convert prospects into Submissions (comprised of revenue share, marketing and advertising expenses and customerconsumer care and enrollment expenses, excluding associated share-based compensation expense, the impact of revenue adjustments recorded in the period, but relating to performance obligations satisfied in prior periods, and such expenses related to our non-EncompassNon-Encompass BPO Services) for such period. The estimate of the future renewal commissions is determined by using the contracted renewal commission rates constrained by a persistency-adjusted renewal period. The persistency-adjusted renewal period is determined based on our historical experience and available industry and health plan partner historical data. Persistency adjustments allow us to estimate renewal revenue only to the extent probable that a material reversal in revenue would not be expected to occur. These factors may result in varying values from period to period. See “Risk Factors—Risks Related to Our Business—Our operating results may be adversely impacted by factors that impact our estimate of LTV” in the 2022our 2023 Annual Report on Form 10-K..10-K.
Cost per Submission refers to (x) the aggregate cost to convert prospects into Submissions during a particular period (comprised of revenue share, marketing and advertising expenses, and customerconsumer care and enrollment expenses, excluding associated share-based compensation expense, the impact of revenue adjustments recorded in the period, but relating to performance obligations satisfied in prior periods, and such expenses related to our non-EncompassNon-Encompass BPO Services) divided by (y) either (i) a completed application with our licensed agent that is submitted to the insurance health plan partner and subsequently approved by the health plan partner during the indicated period, excluding applications through our non-EncompassNon-Encompass BPO Services or (ii) a transfer by our agent to the health plan partner through the Encompass marketplace during the indicated period.
GoHealth, Inc.2024 Form 10-Q  29


The following are our Sales/Cost of Submission, Cost of Submission (in thousands) and Cost Per Submission for the three and six months ended June 30, 2023March 31, 2024 and 2022.2023.
Three months ended Jun. 30,Six months ended Jun. 30,
2023202220232022
Three months ended Mar. 31,
Three months ended Mar. 31,
Three months ended Mar. 31,
2024
2024
2024
Sales/Cost of Submission
Sales/Cost of Submission
Sales/Cost of SubmissionSales/Cost of Submission1.2 1.0 1.3 1.1 
Cost of SubmissionCost of Submission$118,080 $142,853 245,250 $345,103 
Cost of Submission
Cost of Submission
Cost per SubmissionCost per Submission$725 $922 651 $830 
Cost per Submission
Cost per Submission
The increases in Sales/Cost of Submission was 1.3 for both the three and six months ended June 30, 2023 compared to the prior year periodsMarch 31, 2024 and the decreases2023. The increase in Cost of Submission and Cost per Submission for both the three and six months ended June 30, 2023March 31, 2024 compared to the prior year periods wereperiod was primarily attributable to an increased investment in our strategic shift towards the Encompass operating model with improved operating efficiencies.targeted marketing efforts and an increased agent headcount, partially offset by a decrease in cost of revenue.
Liquidity and Capital Resources
Overview
Our liquidity needs primarily include working capital and debt service requirements. At June 30, 2023,March 31, 2024, cash and cash equivalents totaled $25.4$97.8 million. We believe that our current sources of liquidity, which include cash and cash equivalents and funds available under the Credit Facilities, as described further below, will be sufficient to meet our projected operating and debt service requirements for at least the next 12twelve months. During the year ended December 31, 2022, we raised $50.0 million through
GoHealth, Inc.2023 Form 10-Q  32


the issuance and sale of Series A redeemable convertible preferred stock. Short-term liquidity needs will primarily be funded through the Revolving Credit Facilities, as described further below, if necessary. As of June 30, 2023, the Company had no amounts outstanding under the Revolving Credit Facilities and had a remaining capacity of $200.0 million.ToTo the extent that our current liquidity is insufficient to fund future activities, we may need to raise additional funds, which may include the sale of equity securities or through debt financing arrangements. The incurrence of additional debt financing would result in debt service obligations and any future instruments governing such debt could provide for operating and financing covenants that could restrict our operations.
The following table presents a summary of cash flows for the sixthree months ended June 30, 2023March 31, 2024 and 2022:2023:
Six months ended Jun. 30,
Three months ended Mar. 31,Three months ended Mar. 31,
(in thousands)(in thousands)20232022(in thousands)20242023
Net cash provided by (used in) operating activitiesNet cash provided by (used in) operating activities$31,340 $6,377 
Net cash provided by (used in) investing activitiesNet cash provided by (used in) investing activities(4,660)(9,658)
Net cash provided by (used in) financing activitiesNet cash provided by (used in) financing activities(17,826)(4,463)
Operating Activities
Cash provided by (used in) operating activities primarily consists of net income (loss) adjusted for certain non-cash items including share-based compensation, depreciation and amortization, amortization of intangible assets, amortization of debt discount and issuance costs, goodwill and intangible impairment charges, operating lease impairment charges, non-cash restructuring charges, non-cash lease expense and the effect of changes in working capital and other activities.
Collection of commissions receivable depends upon the timing of the receipt of commission payments. If there were to be a delay in receiving a commission payment from a health plan partner within a quarter, the operating cash flows for that quarter could be adversely impacted.
A significant portion of marketing and advertising expense is driven by the number of qualified prospects required to generate the Submissions. Marketing and advertising costs are expensed and generally paid as incurred and since commissioncommissions revenue is recognized upon approval of a submission but commission payments are paid to us over time, there are working capital requirements to fund the upfront cost of acquiring new policies.
Net cash provided by operating activities was $31.3$12.5 million for the sixthree months ended June 30, 2023,March 31, 2024, compared to $6.4$20.5 million for the sixthree months ended June 30, 2022.March 31, 2023. The $25.0$8.0 million increasedecrease was primarily driven by aworking capital components. In the current year, the Company paid $10.5 million toward the Securities Class Action settlement which is reflected in the decrease in net loss of $58.2 million, an increase in accounts payable of $19.4 million, a decrease in commissions receivable of $17.9 million, an increase in accrued liabilities of $16.4$10.9 million. Other significant changes in working capital include an increase in cash from commissions payable of $20.3 million, accounts receivable of $12.3 million and a decrease in prepaid expenses and other assetsdeferred revenue of $4.7$11.2 million partially offset by a decrease in deferred revenuecash from commissions receivable of $25.0$26.0 million, a decrease in commissionsaccounts payable of $24.3$8.1 million, a decrease in operating lease impairment chargesprepaid expense and other current assets of $22.3 million, an increase in accounts receivable of $9.9$4.5 million and other adjustments for non-cash itemsliabilities of $10.2$2.7 million.
Investing Activities
GoHealth, Inc.2024 Form 10-Q  30


Net cash used in investing activities decreasedincreased to $4.7$4.6 million for the sixthree months ended June 30, 2023,March 31, 2024, from $9.7$2.2 million for the sixthree months ended June 30, 2022.March 31, 2023. The decreaseincrease was primarily driven by a decreasean increase in capitalized internal-use software related to new technology, software, and systems, as well as a decrease in purchases of property and equipment.systems.
Financing Activities
Net cash used in financing activities was $17.8$0.9 million for the sixthree months ended June 30, 2023, up from $4.5March 31, 2024, compared to $2.4 million for the sixthree months ended June 30, 2022.March 31, 2023. The increasedecrease was primarily driven by a $12.8$1.4 million increasepaydown of debt that did not occur in the repaymentfirst quarter of borrowings.2024.
Credit Facilities
Term Loan Facilities
As of June 30,March 31, 2024 and December 31, 2023, the Company had a principal amount of $110.4 million, $296.3 million and $96.1 million outstanding under the Incremental Term Loan Facility, the 2021 Incremental Term Loans, and the 2021-2 Incremental Term Loans, respectively. The Term Loan Facilities’ effective interest rates were 12.8%12.9% and 13.0% at June 30, 2023.March 31, 2024 and December 31, 2023, respectively.
The
During 2024 the Company is required to repay $75.0 million in aggregate of borrowings under the Term Loan Facilities are payable in quarterly installments in the principal amount of 0.25% of the original principal amount.Facilities. The remaining unpaid balance on the Term Loan Facilities, together with all accrued and unpaid interest thereon, is due and payable on or prior to September 13, 2025.
GoHealth, Inc.2023 Form 10-Q  33


Mandatory Prepayments
During the second quarter of 2023, the Company made a $14.0 million mandatory prepayment to its lenders in connection with fiscal year 2022. Principal repayment obligations are reduced by the amount of any prepayment, and as such, the $14.0 million prepayment during the second quarter of 2023 satisfied the Company’s principal repayment obligations through the second quarter of 2025. No other mandatory prepayments have been required or made during the three and six months ended June 30, 2023. See Note 4, “Long-Term Debt,” to the Condensed Consolidated Financial Statements in this Quarterly Report on Form 10-Q for additional information regarding the Company’s mandatory prepayment.Term Loan Facilities.
Revolving Credit Facilities

The Company collectively refers tohad no amounts outstanding under the Revolving Credit Facility, the IncrementalFacilities as of both March 31, 2024 and December 31, 2023. The Revolving Credit Facilities have a remaining capacity of $111.5 million and $200.0 million in the Incremental No. 4 Revolving Credit Facilityaggregate as the “Revolving Credit Facilities”. Theof March 31, 2024 and December 31, 2023, respectively. The Revolving Credit Facilities are separated into two classes of revolving commitments consistingcommitments. After the adoption of Amendment No. 11 to the Credit Agreement, the New Class A Revolving Commitments in the amount of $30.0 millionmature on June 30, 2025 and bear interest at either ABR plus 5.5% per annum or SOFR plus 6.5% per annum. The Remaining Class B Revolving Commitments in the amount of $170.0 million.
The Company had no amounts outstanding under the Class A Revolving Credit Facilities and Class B Revolving Credit Facilities as of both June 30, 2023 and December 31, 2022. The Revolving Credit Facilities have a remaining capacity of $200.0 million in the aggregate as of June 30, 2023.
Outstanding borrowings under the Revolving Credit Facilities do not amortize and are due and payablemature on September 13, 2024.
2024 and bear interest at either ABR plus 3.0% per annum or SOFR plus 4.0% per annum. See Note 4, “Long-Term Debt,” to the Condensed Consolidated Financial Statements in this Quarterly Report on Form 10-Q for additional information regarding the Company’s Revolving Credit Facilities.
Recent Accounting Pronouncements
For a discussion of new accounting pronouncements recently adopted and not yet adopted, see Part 1, Note 1, “Description Of Business And Significant Accounting Policies,” to the Condensed Consolidated Financial Statements included elsewhere in this Quarterly Report on Form 10-Q.
Critical Accounting Policies and Estimates
The preparation of ourthe Condensed Consolidated Financial Statements and related disclosures in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of revenues, expenses, assets, and liabilities and the disclosure of contingent assets and liabilities in our financial statements.liabilities. We regularly assess these estimates; however, actual amounts could differ from those estimates. The most significant items involving management’s estimates include estimates of revenue recognition, commissions receivable, and commissions payable. The impact of changes in estimates is recorded in the period in which they become known.
An accounting policy is considered to be critical if the nature of the estimates or assumptions is material due to the levels of subjectivity and judgment necessary to account for highly uncertain matters or the susceptibility of such matters to change, and the effect of the estimates and assumptions on financial condition or operating performance. The accounting policies we believe to reflect our more significant estimates, judgments and assumptions that are most critical to understanding and evaluating our reported financial results are: (1)
Commission revenue recognition and commissions receivable, (2) share-based compensation, (3) intangible assets, (4) impairmentreceivable;
Share-based compensation;
Intangible assets;
Impairment of operating lease ROU assets, (5) income taxes and (5) liabilitiesassets;
Liabilities pursuant to tax receivable agreements (“TRAs”).the TRA.
GoHealth, Inc.2024 Form 10-Q  31


Our critical accounting policies are described under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Critical Accounting Policies”Policies and Estimates” in our 20222023 Annual Report on Form 10-K. During the three and six months ended June 30, 2023,March 31, 2024, there were no material changes to our critical accounting policies from those discussed in our 20222023 Annual Report on Form 10-K.
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.
As a smaller reporting company, we are not required to include disclosure under this item.
ITEM 4. CONTROLS AND PROCEDURES
Limitations on Effectiveness of Controls and Procedures
In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that
GoHealth, Inc.2023 Form 10-Q  34


management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.
Evaluation of Disclosure Controls and Procedures

Our management with the participation of our chief executive officeris responsible for establishing and chief financial officer, evaluated, as of the end of the period covered by this Quarterly Report on Form 10-Q, the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Based on that evaluation, our chief executive officer and chief financial officer concluded that our disclosure controls and procedures were not effective as of June 30, 2023, because of the material weakness inmaintaining adequate internal control over financial reporting described below. A material weakness(as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act). Internal control over financial reporting is a deficiency,process designed under the supervision of the Company’s Chief Executive Officer and Chief Financial Officer, and effected by the Company’s Board of Directors, management and other personnel to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP and includes those policies and procedures that:

1.Pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the Company;

2.Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the Company; and

3.Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the Company’s assets that could have a combinationmaterial effect on the financial statements.

Our management conducted an evaluation of deficiencies, inthe effectiveness of our internal control over financial reporting suchas of March 31, 2024, utilizing the framework in Internal Control-Integrated Framework (2013) established by the Committee of Sponsoring Organizations (COSO) of the Treadway Commission. Our internal control over financial reporting includes policies and procedures that there is aare designed to provide reasonable possibility that a material misstatementassurance regarding the reliability of our annual or interimfinancial reporting and the preparation of financial statements will not be prevented or detected on a timely basis.

for external reporting purposes in accordance with GAAP. Based on this evaluation and those criteria, our management concluded that our internal control over financial reporting was ineffectiveeffective as of June 30, 2023, because we identified a material weakness related to the ineffective design and operation of process level controls that addressed the completeness and accuracy of key financial data utilized in the recognition of commission revenue, including estimating the total constrained lifetime value of commission revenue and the related revenue share and balance sheet accounts, and the Company did not retain sufficient contemporaneous documentation to demonstrate the operation of review controls over commission revenue at a sufficient level of precision. We reviewed the results of our management’s assessment with our Audit Committee.March 31, 2024.

We continue to strengthen our internal control over financial reporting and are committed to ensuring that such controls are designed and operating effectively. We will be implementing process and control improvements to address the above material weakness that include, but are not limited to: i) establishing specific management review procedures to ensure completeness and accuracy of key financial data utilized in the recognition of commission revenue and the contemporaneous documentation of such reviews, ii) providing additional training related to validating the accuracy of data used in key review controls and the level of documentation required, and iii) investing in our corporate infrastructure to ensure adequate technology and resources to support our financial reporting process and internal control framework. During the second quarter of 2022, the Company hired a Chief Actuarial Officer who has been partnering with our data scientists, to bring additional experience and oversight of commission revenue and its related process and controls.

When fully implemented and operational, we believe the measures described above will remediate the control deficiencies that have led to the material weakness.

Notwithstanding the existence of the material weakness as described above, ourOur management has concluded that the Condensed Consolidated Financial Statements included in this Quarterly Report on Form 10-Q fairly present, in all material respects, our financial position, results of operations and cash flows as of the dates, and for the periods presented, in conformity with U.S. GAAP.

Changes in Internal Control over Financial Reporting
Except for the material weakness identified above, thereThere were no changes in our internal controls over financial reporting identified in management’s evaluation pursuant to Rules 13a-15(d) or 15d-15(d) of the Exchange Act during the quarter ended June 30, 2023March 31, 2024 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
GoHealth, Inc.20232024 Form 10-Q  3532


PART II - Other Information
ITEM 1. LEGAL PROCEEDINGS.
Refer to Note 11, “Commitments And Contingencies,” of the Notes to the Condensed Consolidated Financial Statements for information about legal proceedings.
ITEM 1A. RISK FACTORS.

Our business could be adversely affected asWe refer you to our 2023 Annual Report on Form 10-K for a result of uncertainty regarding proposals or other actions taken by stockholders related to the consideration of a possible future transaction.

In May 2023, our Board of Directors received an unsolicited proposal from a group of buyers that includes Centerbridge and the Founders to acquire alldiscussion of the outstanding shares of Class A common stock and LLC Interests not already owned by the potential buyers. In August 2023, we announcedrisk factors that following careful review and consideration with its independent financial and legal advisors, a Special Committee of the Board of the Directors rejected this proposal. Addressing the unsolicited proposal, similar future proposals and any other actions by stockholders or others relating to a potential transaction involving ownership of the Company could interfere with our ability to execute our strategic plans, make it more difficult to attract and retain qualified executives and employees, cause management distraction, require us to utilize more resources than anticipated towards review of strategic alternatives and result in the loss of potential business opportunities, any of which could have a material negative impact on the Company. In addition,affect our business and operations may be harmed to the extent that our customers, suppliers and others believe that we cannot effectively compete in the marketplace without completing a transaction, or there is customer, supplier or employee uncertainty surrounding the future direction of the product and service offerings and our strategy on a continued basis. There can befinancial results.There have been no assurance that any transaction will be completed now or in the future.

Further, the unsolicited proposal, similar future proposals and any actual or perceived actions by our stockholders or others relating to a potential transaction involving the Company may cause significant fluctuationsmaterial changes in our stock price based upon temporary or speculative market perceptions or otherrisk factors that do not necessarily reflect the Company’s underlying fundamentals and prospects.from those disclosed in our 2023 Annual Report on Form 10-K.
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.
None.
ITEM 3. DEFAULTS UPON SENIOR SECURITIES.
None.
ITEM 4. MINE SAFETY DISCLOSURES.
Not applicable.None.
ITEM 5. OTHER INFORMATION.

None.During the fiscal quarter ended March 31, 2024, none of our directors or officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted, modified, or terminated a Rule 10b5-1 trading plan or a non-Rule 10b5-1 trading arrangement for our securities (as defined in Item 408(c) of Regulation S-K).

On May 8, 2024, GoHealth, Inc. (the “Company”) and GoHealth Holdings, LLC signed an Amended and Restated Employment Agreement (the “Employment Agreement”) with one of its named executive officers, Michael Hargis. The Employment Agreement updates the previous employment agreement entered into with Mr. Hargis in connection with his role as Chief Customer Experience Officer. The Employment Agreement states the base salary, bonus and shares of common stock issuable pursuant to restricted stock units that were established at the time he assumed the role of Chief Operating Officer on July 31, 2023 and have been previously described in the Executive Compensation Overview of the Company’s Definitive Proxy Statement filed with the Securities and Exchange Commission on April 26, 2024. In addition, the Employment Agreement states that in the event of a termination of Mr. Hargis by the Company without cause or Mr. Hargis’ resignation for good reason, Mr. Hargis will receive (i) one year of salary continuation, unless such termination occurs within twelve (12) months of a change in control, in which case the period is increased to two (2) years; (ii) the annual bonus for any completed fiscal year as of the date of termination that has not yet been paid as of the date of termination (“Prior Year Bonus”), if any, plus a pro-rated portion of the annual bonus for the year in which the date of termination occurs based on the number of months for which Mr. Hargis was employed during such year prior to the date of termination (“Pro-Rated Bonus”), unless such termination occurs within twelve (12) months of a change in control, in which case the severance bonus shall be equal to the sum of the Prior Year Bonus, if any, and the product of two (2) multiplied by the Pro-Rated Bonus; and (iii) reimbursement of one year of the Company’s share of COBRA premium payments in an amount equal to what the Company pays for the health insurance premiums of other executive level employees at the Company, unless such termination occurs within twelve (12) months of a change in control, in which case the period is increased to two (2) years and (iv) twelve (12) months of continued vesting for any and all unvested Restricted Stock Units, Performance Stock Units, and/or options granted to Mr. Hargis that are scheduled to occur within twelve (12) months following Mr. Hargis’ termination date; in each case subject to Mr. Hargis executing a release of claims in favor of the Company and complying with any restrictive covenants through the period of payment.

The foregoing summary of the terms of the Employment Agreement does not purport to be complete and is qualified in its entirety by reference to the Employment Agreement, a copy of which is attached hereto as Exhibit 10.2.
GoHealth, Inc.20232024 Form 10-Q  3633


ITEM 6. EXHIBITS.
Exhibit Index
 Incorporated by Reference   Incorporated by Reference 
Exhibit
Number
Exhibit
Number
DescriptionFormFile No.ExhibitFiling
Date
Filed/
Furnished
Herewith
Exhibit
Number
DescriptionFormFile No.ExhibitFiling
Date
Filed/
Furnished
Herewith
3.13.110-Q001-393903.18/20/2020
3.23.210-Q001-393903.28/20/2020
3.2
3.2
3.3
3.3
3.33.38-K001-393903.19/26/2022
3.43.48-K001-393903.29/26/2022
3.4
3.4
4.14.1S-1333-2392874.16/19/2020
4.210-K01-393904.23/16/2021
4.1
4.1
10.1#*
31.1*
31.2*
32.1**
32.2**
101.INSInline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.*
101.SCHInline XBRL Taxonomy Extension Schema Document*
101.CALInline XBRL Taxonomy Extension Calculation Linkbase Document*
101.DEFInline XBRL Taxonomy Extension Definition Linkbase Document*
101.LABInline XBRL Taxonomy Extension Label Linkbase Document*
101.PREInline XBRL Taxonomy Extension Presentation Linkbase Document*
104Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)*
10.110-K001-3939010.103/14/2024
10.2#*
31.1*
31.2*
32.1**
32.2**
101.INSInline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.*
101.SCHInline XBRL Taxonomy Extension Schema Document*
101.CALInline XBRL Taxonomy Extension Calculation Linkbase Document*
101.DEFInline XBRL Taxonomy Extension Definition Linkbase Document*
101.LABInline XBRL Taxonomy Extension Label Linkbase Document*
101.PREInline XBRL Taxonomy Extension Presentation Linkbase Document*
104Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)*
*    Filed herewith.
**    Furnished herewith.
#    Indicates management contract or compensatory plan.
GoHealth, Inc.20232024 Form 10-Q  3734


SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
GoHealth, Inc.
(Registrant)
Date:August 10, 2023May 9, 2024By:/s/ Vijay Kotte
Vijay Kotte
Chief Executive Officer
(Principal Executive Officer)
Date:August 10, 2023May 9, 2024By:/s/ Jason Schulz
Jason Schulz
Chief Financial Officer
(Principal Financial and Accounting Officer)
GoHealth, Inc.20232024 Form 10-Q  3835